Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. by Planchard, D et al.
CLINICAL PRACTICE GUIDELINES
Metastatic non-small cell lung cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment
and follow-up†
D. Planchard1, S. Popat2, K. Kerr3, S. Novello4, E. F. Smit5, C. Faivre-Finn6, T. S. Mok7, M. Reck8,
P. E. Van Schil9, M. D. Hellmann10 & S. Peters11, on behalf of the ESMO Guidelines Committee*
1Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; 2Royal Marsden Hospital, London; 3Aberdeen Royal Infirmary, Aberdeen
University Medical School, Aberdeen, UK; 4Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy; 5Thoracic Oncology Service,
Netherlands Cancer Institute, Amsterdam, The Netherlands; 6Division of Cancer Sciences, University of Manchester, Manchester, UK; 7Department of Clinical
Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China; 8LungenClinic Airway Research Center North (ARCN), German Center
for Lung Research, Grosshansdorf, Germany; 9Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp,
Belgium; 10Weill Cornell Medical College, New York, USA; 11Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, CH-6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org
†Approved by the ESMO Guidelines Committee: February 2002, last update September 2018. This publication supersedes the previously published version—Ann Oncol
2016; 27 (Suppl 5): v1–v27.
Incidence and epidemiology
Primary lung cancer remains the most common malignancy after
non-melanocytic skin cancer, and deaths from lung cancer ex-
ceed those from any other malignancy worldwide [1]. In 2012,
lung cancer was the most frequently diagnosed cancer in males
with an estimated 1.2 million incident cases worldwide. Among
females, lung cancer was the leading cause of cancer death in
more developed countries and the second leading cause of cancer
death in less developed countries [1]. The highest incidence is
found in Central/Eastern Europe and Asia with age-standardised
incidence rates of 53.5 and 50.4 per 100 000, respectively.
European projections for 2017 indicate a 10.7% drop in 5 years
with an incidence of 33.3/100 000 in males and a rise of 5.1% and
an incidence of 14.6/100 000 in females [2]. Contrary to the
United States, the death rate in females is increasing in Europe
[3]. The number of lung cancer-related deaths in Europe for 2017
is estimated to represent the leading cause of cancer deaths in
both genders, accounting for 24% in males and 15% in females,
respectively [2].
Non-small cell lung cancer (NSCLC) accounts for 80%–90%
of lung cancers, while small cell lung cancer (SCLC) has been
decreasing in frequency in many countries over the past two dec-
ades [4]. During the last 25 years, the distribution of histological
types of NSCLC has changed: in the United States, squamous cell
carcinoma (SCC), formerly the predominant histotype, decreased,
while adenocarcinoma has increased in both genders. In Europe,
similar trends have occurred in men, while in women, both SCC
and adenocarcinoma are still increasing [5].
The World Health Organization (WHO) estimates that lung
cancer is the cause of 1.59 million deaths globally per year, with
71% of them caused by smoking. Tobacco smoking remains the
main cause of lung cancer and the geographical and temporal
patterns of the disease largely reflect tobacco consumption dur-
ing the previous decades. Both smoking prevention and smoking
cessation can lead to a reduction in a large fraction of lung can-
cers [6]. In countries with active tobacco control measures, the
incidence of lung cancer has begun to decline in men and is
reaching a plateau for women [1, 7–9]. Several other factors have
been described as lung cancer risk factors, including exposure to
asbestos, arsenic, radon and non-tobacco-related polycyclic aro-
matic hydrocarbons. Hypotheses about indoor air pollution (e.g.
coal-fuelled stoves and cooking fumes) are made for the relatively
high burden of non-smoking-related lung cancer in women in
some countries [10]. There is evidence that lung cancer rates are
higher in cities than in rural settings but many confounding fac-
tors other than outdoor air pollution may be responsible for this
pattern.
About 500 000 deaths annually are attributed to lung cancer in
lifetime never-smokers [1]. Absence of any history of tobacco
smoking characterises 19% of female compared with 9% of male
lung carcinoma in the United States [11, 12]. An increase in the
proportion of NSCLC in never-smokers has been observed, espe-
cially in Asian countries [13]. These new epidemiological data
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have resulted in ‘non-smoking-associated lung cancer’ being con-
sidered a distinct disease entity, where specific molecular and
genetic tumour characteristics have been identified [14].
Use of non-cigarette tobacco products such as cigars and pipes
has been increasing. A pooled analysis highlighted the increased
risk, particularly for lung and head and neck cancers, in smokers
(former and current) of cigars and pipes [15].
Familial risk of lung cancer has been reported in several
registry-based studies after careful adjustment for smoking [16].
A recent study estimated the heritability of lung cancer at 18%
but many of the genetic components remain unidentified.
Genome-wide association studies (GWAS) have identified lung
cancer susceptibility loci including CHRNA3, CHRNA5, TERT,
BRCA2, CHECK2 and the human leukocyte antigen (HLA) re-
gion [17–19]. Another trial, including data from 29 266 cases and
56 450 controls from European descent, found 18 susceptibility
loci reaching genome-wide significance, among which 10 were
previously unknown. Interestingly, while four of the latter were
associated with overall lung cancer risk, six were associated with
lung adenocarcinoma only [20].
Diagnosis and pathology/molecular biology
Diagnosis
Changes in the therapeutic scenario in the last 15 years have
emphasised the need for a multidisciplinary approach in lung
cancer. Data show that high-volume centres and multidisciplin-
ary teams are more efficient at managing patients with lung can-
cer than low-volume or non-multidisciplinary centres, by
providing more complete staging, better adherence to guidelines
and increased survival [21, 22]. Multidisciplinary tumour boards
influence providers’ initial plans in 26%–40% of cases [23]. The
absolute need to reach a proper and precise morphological and
biological definition often requires challenging tissue sampling,
with most treatment decisions depending on the information
obtained from the specimen collected at diagnosis.
Bronchoscopy is a technique ideally suited to large, central lesions
and offers the advantage of minimal morbidity. Bronchoscopy can
be used for bronchial washing, brushing, bronchial and transbron-
chial biopsy, with a diagnostic yield of 65%–88% [24–26]. By com-
bining direct bronchoscopic airway visualisation with ultrasound-
guided biopsy of the lesion, endobronchial ultrasound (EBUS) pro-
vides a diagnostic yield of 75%–85% in large, centrally located
lesions [27, 28]. Fibre optic bronchoscopy allows for the evaluation
of regional lymph nodes by EBUS and/or endoscopic ultrasound
(EUS). EBUS-guided transbronchial needle aspiration (TBNA) is
less invasive and at least as accurate as mediastinoscopy [29]. Several
studies have shown that cytological specimens obtained by EBUS-
TBNA are suitable for molecular testing for epidermal growth factor
receptor (EGFR), Kirsten rat sarcoma viral oncogene homologue
(KRAS) and anaplastic lymphoma kinase (ALK) status [30–33];
however, collection of samples suitable for broader molecular diag-
nostic testing should be encouraged.
In case of peripheral lesions, transthoracic percutaneous fine
needle aspiration and/or core biopsy, under imaging guidance
[typically computed tomography (CT)] is proposed [34]. Needle
biopsy is associated with a diagnostic accuracy of > 88% yield, a
sensitivity of 90% and a false-negative rate of 22% [25, 35–38].
The most significant disadvantage of transthoracic needle biopsy
is a procedural risk of pneumothorax, ranging from 17% to 50%
[37, 38].
In the presence of a pleural effusion, thoracentesis could repre-
sent both a diagnostic tool and a palliative treatment. If fluid
cytology examination is negative, image-guided pleural biopsy or
surgical thoracoscopy should be carried out. More invasive, sur-
gical approaches [mediastinoscopy, mediastinotomy, thoraco-
scopy, video-assisted thorascopic surgery (VATS), secondary
lesion resection etc.] in the diagnostic workup are considered
when the previously described techniques cannot allow for an ac-
curate diagnosis.
Pathology/molecular biology
Histological diagnosis. Histological diagnosis of NSCLC is crucial
to many treatment decisions and should be as exact and detailed
as the samples and available technology allow. Diagnosis should
be based upon the criteria laid out in the WHO classification
[39]. This classification details the complete diagnostic approach
for surgically resected tumours but, importantly, also provides
guidance for assessing and reporting small biopsy and cytology
samples where complete morphological criteria for specific diag-
nosis may not be met [39–41].
Most patients with NSCLC present with advanced stage unre-
sectable disease, therefore all treatment-determining diagnoses
must be made on small biopsy and/or cytology-type samples.
Sampling may be carried out of the primary tumour or any ac-
cessible metastases, taken under direct vision or more usually
with image-guided assistance, which greatly increases the diag-
nostic yield (hit rate). Sampling metastatic disease may facilitate
staging, as well as diagnosis. These diagnostic samples frequently
have limited tumour material and must therefore be handled ac-
cordingly; ensuring processing is suitable for all likely diagnostic
procedures and that material is used sparingly at each step, since
many diagnostic tests may be required [42].
Immunohistochemistry (IHC) has become a key technique in
primary diagnosis as well as in predictive biomarker assessment.
In those cases of NSCLC where specific subtyping is not possible
by morphology alone, a limited panel of IHC is recommended to
determine the subtype [39, 40]. Thyroid transcription factor 1
(TTF1) positivity is associated with probable diagnosis of adeno-
carcinoma, p40 positivity with probable diagnosis of SCC; if nei-
ther are positive the diagnosis remains NSCLC-not otherwise
specified (NOS). IHC staining should be used to reduce the
NSCLC-NOS rate to< 10% of cases diagnosed [IV, A]. Pathologists
are urged to conserve tissue at every stage of diagnosis, to use only
two tissue sections for IHC NSCLC subtyping and to avoid excessive
IHC investigation, which may not be clinically relevant.
Molecular diagnostics. After morphological diagnosis, the next
consideration is therapy-predictive biomarker testing. This prac-
tice will be driven by the availability of treatments and will vary
widely between different geopolitical health systems [43–45].
Contemporary practice has now evolved into two testing streams,
one for the detection of targetable, usually addictive, oncogenic
alterations and the other for immuno-oncology therapy
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biomarker testing. A personalised medicine synopsis table is
shown in Table 1.
Several molecular drivers for oncogene addiction represent
strong predictive biomarkers and excellent therapeutic targets.
They are generally mutually exclusive of each other [43–45].
These tumours are much more common in never- (never smoked
or who smoked < 100 cigarettes in lifetime), long-time ex-
(> 10 years) or light-smokers (< 15 pack-years) but they can also
be found in patients who smoke. The vast majority of oncogene-
addicted lung cancers are adenocarcinomas. Patients, in general,
tend to be younger, while female gender and East Asian ethnicity
particularly enriches for EGFR-mutant tumours. Nonetheless,
guidelines suggest that all patients with advanced, possible, prob-
able or definite, adenocarcinoma should be tested for oncogenic
drivers [43–46]. Molecular testing is not recommended in SCC,
except in those rare circumstances when SCC is found in a never-,
long-time ex- or light-smoker (< 15 pack-years) [IV, A]. Testing
for EGFR mutations and rearrangements involving the ALK and
ROS1 genes are now considered mandatory in most European
countries. BRAFV600Emutations are rapidly approaching this sta-
tus as first-line BRAF/MEK inhibitors are more widely approved,
while HER2 (human epidermal growth factor receptor 2) and
MET exon 14 mutations and fusion genes involving RET and
NTRK1 (neurotropic tropomyosin receptor kinase 1) are evolving
targets/biomarkers [43–46].
EGFR tyrosine kinase inhibitors (TKIs) are established effective
therapies in patients who have activating and sensitising muta-
tions in exons 18–21 of EGFR [47]. Prevalence is around 10%–
20% of a Caucasian population with adenocarcinoma but much
higher in Asian population. Around 90% of the most common
mutations comprise deletions in exon 19 and the L858R substitu-
tion mutation in exon 21. Any testing approach must cover these
mutations [I, A]; however, complete coverage to include exons
18–21 is recommended [III, B]. The T790M exon 20 substitution
mutation is only rarely found in EGFR TKI-naive disease using
standard techniques but is the most frequent cause of resistance
to first- and second-generation EGFR TKIs (50%–60% of cases).
Cases of patients carrying germline T790M mutation have also
been reported [48]. Further studies to better understand the
prevalence, familial penetrance and lifetime lung cancer risk in
germline T790M-mutant patients are warranted. Implications of
this mutation in TKI-naive disease are unclear, but the availabil-
ity of TKIs effective against T790M-mutant recurrent disease
makes T790M testing on disease relapse mandatory [I, A]. Cell-
free DNA (cfDNA) blood testing is an acceptable approach to de-
tect T790M at relapse but lacks sensitivity, so all patients with a
negative blood test still require tissue biopsy [II, A] [49]. Tissue
biopsy may also be more effective in identifying other resistance
mechanisms which may require alternative treatment (SCLC
transformation, MET amplification, HER2 alterations etc.).
Table 1. A personalised medicine synopsis table for metastatic NSCLC
Biomarker Method Use LoE, GoR
EGFR mutation Any appropriate, validated method, subject to external qual-
ity assurance
To select those patients with EGFR-sensitising muta-
tions most likely to respond to EGFR TKI therapy
I, A
ALK rearrangement Any appropriate, validated method, subject to external qual-
ity assurance. FISH is the historical standard but IHC is
now becoming the primary therapy-determining test,
provided the method is validated against FISH or some
other orthogonal test approach. NGS is an emerging
technology
To select those patients with ALK gene rearrange-
ments most likely to respond to ALK TKI therapy
I, A
ROS1 rearrangement FISH is the trial-validated standard. IHC may be used to se-
lect patients for confirmatory FISH testing but currently
lacks specificity. NGS is an emerging technology. External
quality assurance is essential
To select those patients with ROS1 gene rearrange-
ments most likely to respond to ROS1 TKI therapy
II, A
BRAF mutation Any appropriate, validated method, subject to external qual-
ity assurance
To select those patients with BRAF V600-sensitising
mutations most likely to respond to BRAF inhibi-
tor, with or without MEK inhibitor therapy
II, A
PD-L1 expression IHC to identify PD-L1 expression at the appropriate level and
on the appropriate cell population(s) as determined by
the intended drug and line of therapy. Only specific trial
assays are validated. Internal and external quality assur-
ance are essential
To enrich for those patients more likely to benefit
from anti-PD-1 or anti-PD-L1 therapy. For pembro-
lizumab, testing is a companion diagnostic for
nivolumab and atezolizumab, testing is
complementary
I, A
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; GoR, grade of recommendation; IHC,
immunohistochemistry; LoE, level of evidence; MEK, mitogen-activated protein kinase kinase; NGS, next-generation sequencing; NSCLC, non-small cell lung
cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor.
Clinical Practice Guidelines Annals of Oncology
iv194 | Planchard et al. Volume 29 | Supplement 4 | October 2018
Fusion genes involving ALK and a number of partners (most
commonly EML4) account for around 2%–5% of the same popu-
lation that is routinely tested for EGFR mutations [50]. ALK-
driven adenocarcinoma is very sensitive to several ALK TKIs.
Early trials validated break-apart fluorescent in situ hybridisation
(FISH) as the test to identify ALK gene rearrangement but the
close association between a positive FISH test and modestly ele-
vated ALK protein in tumour cells allows ALK IHC to be used,
either to select cases for confirmatory FISH testing or as the pri-
mary therapy-determining test [50, 51]. ALK IHC must reliably
detect low levels of ALK protein and be validated against alterna-
tive tests to detect ALK fusion genes, especially if ALK IHC is
used as the therapy-determining assay, without confirmation by
FISH [II, A]. Emerging data demonstrate that the presence of the
ALK protein (positive IHC staining) is associated with treatment
response [I, A] [52, 53]. Recently, IHC has been accepted as an
equivalent alternative to FISH for ALK testing [54]. Testing for
ALK rearrangement should be systematically carried out in
advanced non-squamous NSCLC [I, A]. ALK mutations are
emerging as important resistance mechanisms to ALK TKIs and
ALK mutation testing may soon become a routine test at relapse
as newer-generation ALK TKIs show differential efficacy against
different ALK mutations [55].
ROS1 fusion genes are yet another addictive oncogenic driver
that occurs in 1%–4% of the same testing population. Like
ALK, ROS1 has several potential fusion gene partners. Crizotinib,
a TKI effective against ALK and MET, is also approved by the
European Medicines Agency (EMA) for use in ROS1-rearranged
adenocarcinomas. FISH has been the standard approach to
detecting ROS1 rearrangements. IHC may be used in a manner
similar to ALK testing, to identify candidate tumours for con-
firmatory FISH testing. The sensitivity of this approach is high,
using currently available IHC, but specificity of IHC is low [IV,
C]. FISH or other testing is required to confirm the diagnosis;
IHC is currently not recommended as the primary treatment
determining test [IV, A] [45, 46, 50]. Testing for ROS1 rearrange-
ment should be systematically carried out in advanced non-
squamous NSCLC [III, A].
BRAF mutation testing is now required in many countries after
the approval of BRAF and MEK inhibitors for BRAF V600-
mutant NSCLC. Any method is valid provided that it is adequate-
ly sensitive for the samples used and has been appropriately
quality-assured, both within the laboratory and through external
quality assurance. The V600E mutation is the most common of
the BRAF V600 family and, overall, these BRAF mutations are
found in 2% of cases. BRAF V600 mutations appear mutually
exclusive to EGFR and KRAS mutations, ALK and ROS1 rear-
rangements and are similarly much more common in adenocar-
cinoma. BRAF V600 mutation status should be systematically
analysed in advanced non-squamous NSCLC for the prescription
of BRAF/MEK inhibitors [II, A].
For many laboratories, testing for EGFR and BRAF mutations
and ALK and ROS1 rearrangements involves individual stand-
alone tests. Multiplex, massively parallel, so-called next-gener-
ation sequencing (NGS) of various sorts is rapidly being adopted
as the standard approach to screening adenocarcinomas for
oncogenic targets [III, A] [45, 49, 50, 56]. Platform-specific, com-
mercially available panels can cover genes of interest and provide
a comprehensive, multiplex test for mutations and, in some cases,
fusion genes. NGS will not address biomarkers that require test-
ing at the protein level (requires IHC) and the question of
whether NGS-detected fusion genes require an orthogonal test
(IHC, FISH) for confirmation remains open. Whatever testing
modality is used, it is mandatory that adequate internal valid-
ation and quality control measures are in place and that laborato-
ries participate in, and perform adequately, external quality
assurance schemes for each biomarker test [III, A].
The approval of the anti-programmed cell death protein 1
(PD-1) agent pembrolizumab as a standard-of-care first-line
treatment in selected patients has made programmed death-
ligand 1 (PD-L1) IHC a mandatory test in all patients with
advanced NSCLC. Although the PD-L1 IHC 22C3 assay was the
only test validated in clinical trials of pembrolizumab, extensive
technical comparison studies suggest that trial-validated com-
mercial kit assays based on the 28-8 and SP263 PD-L1 IHC clones
may be alternative tests [III, A] [57–61]. If laboratories use, by
choice or force of circumstances, a non-trial-validated PD-L1
IHC test, i.e. a laboratory developed test (LDT), there is a high
risk that the assay may fail quality assurance and a very careful,
extensive validation is essential before clinical use [IV, A]
[35, 36]. There is a relationship between the extent of PD-L1 ex-
pression on tumour cells, or in some trials in tumour infiltrating
immune cells, and the probability of clinical benefit from numer-
ous anti-PD-1 or PD-L1 agents, in first- and second-line therapy
[57]. For pembrolizumab, the mandatory treatment threshold is
a tumour proportion score (TPS, presence of PD-L1 signal on tu-
mour cell membranes)  50% in first line and  1% in second
line [62, 63]. PD-L1 expression testing is recommended for all
patients with newly diagnosed advanced NSCLC [I, A]. For nivo-
lumab and atezolizumab in second line, PD-L1 testing is not
required for drug prescription. PD-L1 IHC is an approved bio-
marker test for immunotherapeutics in NSCLC but it is not a per-
fect biomarker; less than half of biomarker-selected patients
benefit from treatment and some responses may be encountered
in ‘biomarker-negative’ cohorts. Much work is underway to iden-
tify alternative, or more likely, additional biomarkers to enrich
patient populations for response. Various measures of tumour
mutational burden (TMB) are being explored and TMB has been
validated prospectively in a unique prospective clinical trial to
date [64]. An international effort is ongoing to define a consensus
on how TMB should be measured [65–67]. Assessment of tu-
mour inflammation is also of interest, but again, various
approaches are being pursued, including histological assessment
of immune cell infiltrates and mRNA-based expression signatures
of immune-related genes. More data are required before any of
these new approaches can be routinely incorporated into NSCLC
biomarker testing.
Blood monitoring. The ability to detect oncogenic driver genomic
alterations, or factors associated with disease resistance to treat-
ment in peripheral blood, opens the way to disease monitoring in
a way that would not be practically feasible were repeat testing
solely based upon tumour biopsy testing. In practice, and with
current knowledge, this is more likely to involve the use of
cfDNA rather than circulating tumour cells (CTCs); the vast ma-
jority of existing data concern EGFR mutation testing in blood
[68]. Currently, much EGFR plasma testing is based upon highly
sensitive allele-specific polymerase chain reaction (ASPCR).
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Plasma genotyping may be considered before undergoing a tu-
mour biopsy to detect the T790M mutation. However, if the
plasma testing is negative for T790M, the tissue biopsy is strongly
recommended to determine T790M status because of the risks of
false-negative plasma results [III, A]. NGS techniques can be
used; as more biomarkers are identified and validated, more
NGS-based gene panels would be available.
Notwithstanding the issues regarding sensitivity of blood test-
ing, potentially clinically valuable information may be derived
from serial blood testing during treatment. For example, the dis-
appearance from the blood of the primary sensitising EGFR mu-
tation is associated with clinical and radiological evidence
of response to EGFR TKIs and is a good prognostic indicator
[IV, C].
After maximum response to EGFR TKI therapy and disappear-
ance of the mutation from the plasma, the reappearance of the
primary sensitising mutation, with or without detection of the
T790M resistance mutation, may be an indicator of ‘biochemical’
disease relapse. This occurrence may predate radiological relapse,
which, in turn, may predate clinical/symptomatic disease relapse.
Currently, such findings are essentially exploratory since there is
no consensus as to when and how any clinical intervention
should be managed. There is no doubt, however, that this kind of
molecular monitoring could, in the future, offer benefit to
patients in a number of different personalised treatment
scenarios.
TMB was evaluated in patient tissue as well as blood samples in
different trials. Unique assays and cut-offs are not yet defined but
preliminary data from the POPLAR and OAK trials found TMB
in blood is associated with improved atezolizumab clinical bene-
fit in patients with NSCLC [69]. Preliminary data suggesting
blood TMB as a predictive biomarker for atezolizumab activity
have recently been presented [70]. A prospective trial in the first-
line setting is exploring the same biomarker [NCT03178552].
Staging and risk assessment
A complete medical history with comorbidities, weight loss, per-
formance status (PS) and physical examination must be
recorded. An exhaustive smoking habit assessment has to be
included, indicating type, quantity and timing.
Laboratory
Standard tests including routine haematology, renal and hepatic
function and bone biochemistry tests are required. The routine
use of serum markers, such as carcinoembryonic antigen (CEA),
is not recommended [IV, B] [71].
The neutrophil to lymphocyte ratio (NLR) is a widely available
blood-based data point, validated in numerous oncological set-
tings as a potential prognostic marker. NLR has been considered
as a potential dynamic marker but further prospective validations
are needed [IV, C] [72, 73].
Radiology
Baseline imaging. A contrast-enhanced CT scan of the chest and
upper abdomen including complete assessment of liver, kidneys
and adrenal glands should be carried out. Imaging of the central
nervous system (CNS) is most relevant in those patients with
neurological symptoms or signs [IV, A]; however, if available,
imaging of the CNS with magnetic resonance imaging (MRI,
preferably with gadolinium enhancement) or CT of the brain
with iodinated contrast should be carried out at diagnosis
[IV, B]. MRI is more sensitive than CT scan [III, B] [74].
Leptomeningeal disease (LMD) is a deadly complication of
solid tumours and has a poor prognosis. Adenocarcinomas are
the most common tumours to metastasise to the leptomeninges.
In case of clinical suspicion, LMD diagnostic imaging should in-
clude the brain and the spinal cord, as LMD can impact the entire
neuraxis. If metastatic disease has been determined by CT scan of
the chest and upper abdomen or by brain imaging, other imaging
is only necessary if it has an impact on treatment strategy. If bone
metastases are clinically suspected, bone imaging is required [IV,
B]. Bone scan or positron emission tomography (PET), ideally
coupled with CT, can be used for detection of bone metastasis
[IV, B]. PET-CT is the most sensitive modality in detecting bone
metastasis [II, B] [75]. Fluorodeoxyglucose (FDG)-PET or PET-
CT has higher sensitivity and specificity than bone scintigraphy
[76]. FDG-PET-CT scan also has high sensitivity for the evalu-
ation of solitary pulmonary nodules, intra-thoracic pathological
lymph nodes and distant metastatic disease [77]. However, the
low sensitivity of this exam in small lesions, in lesions close to
FDG-avid structures (overprojection) or in lesions that move ex-
tensively, such as those just above the diaphragm, should be con-
sidered. MRI may complement or improve the diagnostic staging
accuracy of FDG-PET-CT imaging, particularly in assessing local
chest wall, vascular or vertebra invasion and is also effective for
identification of nodal and distant metastatic disease. NSCLC is
staged according to the American Joint Committee on Cancer
(AJCC)/Union for International Cancer Control (UICC) system
(8th edition) and is grouped into the stage categories shown in
Tables 2 and 3 [78, 79].
In the presence of a solitary metastatic lesion on imaging stud-
ies, including pleural and pericardial effusion, efforts should be
made to obtain a cytological or histological confirmation of stage
IV disease [IV, A].
Response evaluation. Response evaluation is recommended after
two to three cycles of chemotherapy (ChT) or immunotherapy,
using the same initial radiographic investigation that demon-
strated tumour lesions [IV, B]. The same procedure and timing
(every 6–9 weeks) should be applied for the response evaluation
in patients treated with targeted therapies and/or immunother-
apy [IV, B]. Follow-up with PET is not routinely recommended,
due to its high sensitivity and relatively low specificity [IV, C].
Measurement of lesions should follow Response Evaluation
Criteria in Solid Tumours (RECIST) v1.1 [IV, A] [80]. The ad-
equacy of RECIST in evaluating response to EGFR or ALK TKI in
respective genetically driven NSCLC is still debatable even if this
remains the standard method of evaluation for these patients [IV,
B]. In these two subgroups of patients (and in other actionable
oncogene alterations), treatment beyond RECIST progression is
a common approach, pursuing clinical benefit more than mor-
phological response. This approach differs from what was carried
out historically with cytotoxic agents. The conventional radio-
logical response criteria are unable to describe pseudoprogression
(PsPD) and can result in underestimation of the therapeutic
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benefit of immune checkpoint blockade. Several radiological cri-
teria have been developed specifically for immunotherapy, to bet-
ter define the tumour response in this context. Two-dimensional
immune-related response criteria (irRC) were proposed in 2009
and modified in 2013 with the immune-related RECIST
(irRECIST) [81, 82]. More recently, the RECIST working group
published a proposition of new criteria called immune-RECIST
(iRECIST), to standardise response assessment among immuno-
therapy clinical trials [83]. A subsequent adaption of RECIST
designed to better capture cancer immunotherapy responses has
been published: immune-modified RECIST (imRECIST) [84].
More data are needed to compare the RECIST, iRECIST,
Table 2. Clinical classification UICC TNM 8 [79]
Primary tumour (T)
TX Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum or bronchial washings but not visual-
ised by imaging or bronchoscopy
T0 No evidence of primary tumour
Tis Carcinoma in situa
T1 Tumour 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more
proximal than the lobar bronchus (i.e. not in the main bronchus)b
T1mi Minimally invasive adenocarcinomac
T1a Tumour 1 cm or less in greatest dimensionb
T1b Tumour more than 1 cm but not more than 2 cm in greatest dimensionb
T1c Tumour more than 2 cm but not more than 3 cm in greatest dimensionb
T2 Tumour more than 3 cm but not more than 5 cm; or tumour with any of the following featuresd
-Involves main bronchus regardless of distance to the carina, but without involvement of the carina
-Invades visceral pleura
-Associated with atelectasis or obstructive pneumonitis that extends to the hilar region either involving part of or the entire lung
T2a Tumour more than 3 cm but not more than 4 cm in greatest dimension
T2b Tumour more than 4 cm but not more than 5 cm in greatest dimension
T3 Tumour more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura,
chest wall (including superior sulcus tumours) phrenic nerve, parietal pericardium; or separate tumour nodule(s) in the same lobe as
the primary
T4 Tumour more than 7 cm or of any size that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent
laryngeal nerve, oesophagus, vertebral body, carina; separate tumour nodule(s) in a different ipsilateral lobe to that of the primary
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct
extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural or pericardial nodules or malignant pleural or pericardial effusione
M1b Single extrathoracic metastasis in a single organf
M1c Multiple extrathoracic metastasis in a single or multiple organs
aTis includes adenocarcinoma in situ and squamous carcinoma in situ.
bThe uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, which may extend proximal to the
main bronchus, is also classified as T1a.
cSolitary adenocarcinoma (not more than 3 cm in greatest dimension), with a predominantly lepidic pattern and not more than 5 mm invasion in greatest
dimension in any one focus.
dT2 tumours with these features are classified T2a if 4 cm or less, or if size cannot be determined and T2b if greater than 4 cm but not larger than 5 cm.
eMost pleural (pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple microscopic examinations of pleural (pericar-
dial) fluid are negative for tumour, and the fluid is non-bloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion
is not related to the tumour, the effusion should be excluded as a staging descriptor.
fThis includes involvement of a single non-regional node.
TNM, tumour, node and metastasis; UICC, Union for International Cancer Control.
Reprinted from [79] with permission from John Wiley & Sons, Inc.
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imRECIST and irRECIST to quantify the differences in outcome
estimation before using of them in clinical practice. Non-
conventional responses and PsPD are very rarely observed in
NSCLC, ranging generally under 5% of all cases, and RECIST
v1.1 should still be used in routine practice [IV, B] [85–88].
Management of advanced/metastatic
NSCLC
The treatment strategy (Figures 1–7) should take into account
factors such as histology, molecular pathology, age, PS, comor-
bidities and the patient’s preferences. Treatment decisions should
ideally be discussed within a multidisciplinary tumour board
who can evaluate and change management plans, including rec-
ommending additional investigations and changes in treatment
modality [89]. Systemic therapy should be offered to all stage IV
patients with PS 0–2 [I, A].
In any stage of NSCLC, smoking cessation should be highly
encouraged: it can improve outcome and smoking may interact
with systemic therapy [II, A]. For example, smoking reduces erlo-
tinib bioavailability [90, 91]. Given the established relationship
between smoking and lung cancer, patients who have smoked
may feel stigmatised or guilty after diagnosis and more pessimis-
tic about their illness and likely outcomes, all of which may have
adverse implications for health-related quality of life (QoL) [92].
For these reasons, healthcare professionals should give clear ad-
vice about the adverse implications of continued smoking and in-
clude smoking cessation programmes in the therapeutic algorithm.
First-line treatment of EGFR- and ALK-negative
NSCLC, PD-L1 50%
Lung cancers were previously considered poorly immunogenic,
with minimal benefit seen in historical studies of cytokine modu-
lation or vaccines. However, the recent development of immune
checkpoint inhibitors has upended this belief and provided proof
of principle that immunotherapy can play an important role in
the treatment of patients with lung cancers.
The phase III KEYNOTE-024 study has established the role for
pembrolizumab as first-line treatment in patients with untreated,
advanced NSCLC and tumour characterised by PD-L1 expression
 50% [62], in absence of EGFR mutation or ALK translocations.
In KEYNOTE-024, 1934 patients were screened to identify 500
patients (30%) with tumour PD-L1 expression  50%. Of these
patients, 305 patients were randomised to receive 200 mg pem-
brolizumab every 3 weeks (up to 2 years) or four to six cycles of
standard platinum-doublet ChT. All efficacy measures favoured
pembrolizumab, including objective response rate (ORR 45%
versus 28%), progression-free survival [PFS, hazard ratio (HR)
0.5, 95% confidence interval (CI) 0.37–0.68, P< 0.001] and over-
all survival (OS, HR 0.6, 95% CI 0.41–0.89, P¼ 0.005). Safety and
QoL also favoured pembrolizumab [93]. Continued follow-up
has further emphasised the effectiveness of pembrolizumab, with
median OS (mOS) doubled in those who received pembrolizu-
mab compared with ChT (30 versus 14 months) [94].
Pembrolizumab is considered a standard first-line option for
patients with advanced NSCLC and PD-L1 expression 50% who
do not otherwise have contraindications to use of immunotherapy
(such as severe autoimmune disease or organ transplantation) [I,
A; European Society for Medical Oncology-Magnitude of Clinical
Benefit Scale (ESMO-MCBS) v1.1 score: 5].
Other studies, KEYNOTE-042 and CheckMate 026, examined
a lower threshold for PD-L1 [66, 95]. Recent results from
KEYNOTE-042, a phase III study of patients with PD-L1 1%
who were randomised to either pembrolizumab or ChT, demon-
strated improved OS in patients treated with pembrolizumab at
three thresholds of PD-L1: 50%, 20% and 1%. The HR for
OS was 0.69, 0.77 and 0.81, respectively. Overall, the preponder-
ance of the OS benefit was driven by patients with  50%, while
no significant increase was seen in those patients with 1%–49%
PD-L1 expression (HR 0.92, 95% CI 0.77–1.11).
In CheckMate 026, patients with untreated, advanced NSCLC
and PD-L1 1% (analysis based on 5% threshold) were rando-
mised to nivolumab or platinum-doublet ChT [66]. There were no
improvements in any efficacy metrics. However, an exploratory
retrospective and unplanned analysis examined the impact of TMB
on benefit of nivolumab. A total of 312 patients (58% of rando-
mised patients) had sufficient tissue for whole exome sequencing.
In those patients with the highest tertile of TMB (> 243 missense
non-synonymous somatic mutations per sample), ORR (47% ver-
sus 28% with ChT) and PFS (HR 0.62, 95% CI 0.38–1.0) favoured
those who received nivolumab. Meanwhile, among patients with
low or medium TMB, ORR was numerically better in those who
received ChT (33% versus 23% with nivolumab).
Overall, these results confirm the benefit of pembrolizumab in
the first-line setting seen in KEYNOTE-024, restricted to patients
with high PD-L1 expression ( 50%).
Table 3. Staging and stage grouping UICC TNM 8 [79]
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IA1 T1mi N0 M0
T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a-c T2a,b N1 M0
T3 N0 M0
Stage IIIA T1a-c T2a,b N2 M0
T3 N1 M0
T4 N0, N1 M0
Stage IIIB T1a-c T2a,b N3 M0
T3, T4 N2 M0
Stage IIIC T3, T4 N3 M0
Stage IV Any T Any N M1
Stage IVA Any T Any N M1a, M1b
Stage IVB Any T Any N M1c
TNM, tumour, node and metastasis; UICC, Union for International Cancer
Control.
Reprinted from [79] with permission from John Wiley & Sons, Inc.
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First-line treatment of EGFR- and ALK-negative
NSCLC disease, regardless of PD-L1 status
Recently, results of the phase III trials KEYNOTE-189,
IMpower150 and IMpower132 have brought new options for the
therapeutic choices in first line of non-squamous NSCLC and tri-
als KEYNOTE-407 and IMpower131 for patients with squamous
NSCLC.
In KEYNOTE-189, patients with metastatic non-squamous
NSCLC, PS 0–1, without sensitising EGFR or ALK mutations,
were randomised to receive pemetrexed and cisplatin or carbo-
platin plus either 200 mg of pembrolizumab or placebo every
3 weeks for 4 cycles, followed by pembrolizumab or placebo for
up to a total of 35 cycles plus pemetrexed maintenance therapy
[96]. The mOS was not reached in the pembrolizumab/ChT arm
versus 11.3 months (95% CI 8.7–15.1) in the ChT arm (HR 0.49;
95% CI 0.38–0.64; P< 0.001). The PFS also favoured the pem-
brolizumab/ChT combination (HR 0.52; 95% CI 0.43–0.64;
P< 0.001). The OS benefit of pembrolizumab/ChT was observed
in all PD-L1 tumour subgroups. Notably, among the PD-L1 TPS
< 1%, there was not a clear PFS benefit with pembrolizumab/
ChT (HR 0.75, 95% CI 0.53–1.05), such that the degree of durable
benefit in this group remains limited. Still, based on the results
from KEYNOTE-189, pembrolizumab in combination with
pemetrexed and a platinum-based ChT should be considered a
standard option in metastatic non-squamous NSCLC [I, A;
ESMO-MCBS v1.1 score: 4].
In IMpower150, the addition of atezolizumab to bevacizumab
plus ChT significantly improved PFS and OS among patients with
metastatic non-squamous NSCLC, regardless of PD-L1 expression
[97]. The PFS was longer in the atezolizumab/bevacizumab/ChT
arm compared with bevacizumab/ChT [median PFS (mPFS) 8.3
versus 6.8 months; HR 0.59; 95% CI 0.50–0.70; P< 0.001].
Survival was longer in the atezolizumab/bevacizumab/ChT arm
compared with bevacizumab/ChT (mOS 19.2 versus 14.7 months;
HR 0.78; 95% CI 0.64–0.96; P¼ 0.02; 12-month OS 67% versus
61%). Results from IMpower150 place the combination of atezoli-
zumab and bevacizumab with carboplatin and paclitaxel as a thera-
peutic option in patients with PS 0–1 with metastatic non-
squamous NSCLC, in absence of contraindications to use of im-
munotherapy [I, A]. Of note, this is the only trial to date also
including patients with EGFR or ALK genetic alterations and dem-
onstrating a stringent OS benefit (PFS HR 0.59, 95% CI 0.37–0.94;
OS HR 0.54, 95% CI 0.29–1.03). This association in EGFR- or
ALK-positive NSCLC patients defines a treatment opportunity for
this subgroup after targeted therapies have been exploited [I, A in
unselected non-squamous NSCLC including EGFR- and ALK-
driven NSCLC, specifically [III, A] for EGFR and [III, B] for ALK
subgroups; not EMA-approved].
Recently, the combination of carboplatin or cisplatin with
pemetrexed and atezolizumab followed by maintenance peme-
trexed and atezolizumab has been shown, in the context of the
IMpower132 trial, to be superior to the ChT doublet followed by
maintenance pemetrexed. An improvement in mPFS from 5.2 to
7.6 months was observed (HR 0.6; 95% CI 0.490.72;
P< 0.0001) while OS was not statistically significantly increased
at the time of analysis with mOS of 18.1 versus 13.6 months (HR
0.81; 95% CI 0.641.03; P= 0.0797), suggesting another poten-
tial treatment opportunity [I, B, not EMA approved] [98].
KEYNOTE-407 is a randomised, placebo-controlled study of
patients with metastatic squamous NSCLC [99]. Patients were
randomised 1:1 to receive carboplatin and paclitaxel every
3 weeks, or albumin-bound paclitaxel (nab-P) weekly plus pem-
brolizumab or placebo for 4 cycles, followed by pembrolizumab
or placebo for a total of 35 treatments. The combination of ChT
plus pembrolizumab was associated with improved ORR (58.4%
versus 35.0%, P¼ 0.0004) and improved OS (HR 0.64, mOS 15.9
versus 11.3 months, P¼ 0.0008). The benefit in OS was seen
across PD-L1 expression strata (TPS < 1% HR 0.61, TPS 1%–
49% HR 0.57, TPS  50% HR 0.64). No new safety concerns
were observed. Results from KEYNOTE-407 place the combin-
ation of pembrolizumab plus carboplatin and paclitaxel or nab-P
as a standard choice in patients with metastatic squamous
NSCLC [I, A; not EMA-approved].
Atezolizumab was studied in patients with metastatic squamous
NSCLC in the IMpower131 study. Patients were randomised
to atezolizumab/carboplatin/paclitaxel, atezolizumab/carboplatin/
nab-P or carboplatin/nab-P [100]. Atezolizumab/carboplatin/nab-
P had improved PFS compared with carboplatin/nab-P (HR 0.715,
P¼ 0.0001), but no improvement in OS was seen at the first in-
terim analysis (mOS 14 versus 13.9 months). More mature data
are needed to evalute the long-term benefit of the strategy; with the
use of atezolizumab with carboplatin and nab-P today representing
an option in patients with metastatic squamous NSCLC [I, B; not
EMA-approved].
One key area of uncertainty is among PD-L1 TPS  50%, as
none of these trials provide a direct comparison between ChT plus
checkpoint inhibitors versus pembrolizumab monotherapy.
However, cross-trial comparison between trials suggest similar OS
outcomes among PD-L1 50%, with very different toxicity pro-
files, suggesting that pembrolizumab monotherapy may remain a
reasonable choice for patients with PD-L1 50% [101].
TMB has shown encouraging results as a predictive biomarker
in retrospective studies in NSCLC and SCLC. The first pre-
specified analysis of TMB as a biomarker was reported in the
phase III trial CheckMate 227, evaluating nivolumab plus ipili-
mumab versus ChT in first-line NSCLC [64]. The TMB cut-off of
10 mutations per megabase (Mb) was determined based on data
from CheckMate 568 based on receiver operating characteristic
(ROC) curves and clinical impact analysis [102]. Patients with
newly diagnosed advanced NSCLC were randomised based on
PD-L1 expression. Those who had PD-L1 TPS  1% received
nivolumab/ipilimumab, nivolumab monotherapy or ChT; and
those with a PD-L1 TPS < 1% received nivolumab/ipilimumab,
nivolumab/ChT or ChT. In patients with high TMB ( 10 muta-
tions/Mb, 44% of assessable patients), nivolumab/ipilimumab
was associated with longer PFS than ChT (HR 0.58; 97.5% CI:
0.41–0.81; P< 0.001), and more than tripling of 1-year PFS
(42.6% versus 13.2%). The PFS benefit with nivolumab/ipilimu-
mab was seen irrespective of PD-L1, wherein the HR similarly
favoured nivolumab plus ipilimumab in patients with a PD-L1
TPS  1% and those < 1% (HR 0.62 and HR 0.48, respectively).
A similar benefit was seen in both squamous and non-squamous
histologies (squamous HR 0.63, non-squamous HR 0.55). Of im-
portance, there was no difference in PFS among patients with
< 10 mutations/Mb (HR 1.07; 95% CI 0.84–1.35).
Grade 3–4 treatment-related adverse events (AEs) leading to
discontinuation were more common with ChT than nivolumab
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plus ipilimumab (36% versus 31%), with more subsequent dis-
continuations with immunotherapy (12% versus 5%).
CheckMate 227 continues for the coprimary endpoint of OS in
PD-L1 selected patients. For now, nivolumab plus ipilimumab
represents an optional treatment regimen for patients with
NSCLC with a high TMB [I, A; not EMA-approved]. Important
questions remain regarding the role of immunotherapy combina-
tions versus PD-1 monotherapy in PD-L1 TPS  50% and how
TMB may inform the optimal use of PD-(L)1 plus ChT versus
immunotherapy alone combinations in NSCLC. Additional clin-
ical data and evaluation of long-term benefit of these new strat-
egies are needed. Physicians and patients will need to conduct
individualised discussions regarding benefit and risks of available
therapies over time.
Overall, the results from the KEYNOTE-024, IMpower150,
KEYNOTE-189, IMpower132, CheckMate 227, KEYNOTE-407
and IMpower131 trials suggest that introducing immunotherapy
will be a standard new approach for most patients with newly diag-
nosed NSCLC.
First-line treatment of NSCLC without actionable
oncogenic driver, with contraindications to use of
immunotherapy
ChT with platinum doublets should be considered in all stage IV
NSCLC patients without an actionable oncogenic driver, without
major comorbidities and PS 0–2 [I, A]. Benefits of ChT versus
best supportive care (BSC), namely a 23% reduction of risk of
death, a 1-year survival gain of 9% and a 1.5-month absolute in-
crease in median survival and improved QoL, were observed irre-
spective of age, sex, histology and PS in two meta-analyses [103–
105]. The survival benefit of two-agent over one-agent ChT regi-
mens was reported in a meta-analysis in 2004; no survival benefit
was observed for three-agent over two-agent regimens [106].
Based on a 2006 meta-analysis, revealing a statistically significant
reduction (equal to 22%) in the risk of death at 1 year for plat-
inum over non-platinum combinations, without induction of
unacceptable increase in toxicity, platinum-based doublets are
recommended in all patients with no contraindications to plat-
inum compounds [I, A] [107]. Neither a large individual trial nor
a meta-analysis found an OS benefit of six versus fewer cycles of
first-line platinum-based doublets, although a longer PFS
coupled with significantly higher toxicity was reported in patients
receiving six cycles [108, 109]. Therefore, four cycles of
platinum-based doublets followed by less toxic maintenance
monotherapy [I, A], or four cycles in patients not suitable for
maintenance monotherapy [I, A], up to a maximum of six [IV,
B], are currently recommended.
Several platinum-based regimens with third-generation cyto-
toxics (paclitaxel, gemcitabine, docetaxel, vinorelbine) have
shown comparable efficacy [110, 111]. The expected toxicity pro-
file should contribute to the selection of the ChT regimen, taking
into account that:
• A recent Cochrane review including 10 trials with 3973
patients available for meta-analysis could not demonstrate
any difference between carboplatin-based and cisplatin-
based ChT in OS. Cisplatin had higher ORRs in an overall
analysis but trials using paclitaxel or gemcitabine plus a
platinum agent in both arms had equivalent response.
Cisplatin caused more nausea or vomiting and carboplatin
caused more thrombocytopaenia and neurotoxicity, while
no difference in the incidence of grade 3-4 anaemia, neutro-
paenia, alopaecia or renal toxicity was observed [112].
• The carboplatin/nab-P regimen has been shown in a large
phase III trial to have a significantly higher ORR compared
with solvent-based paclitaxel/carboplatin (sb-PC), and less
neurotoxicity [I, B] [113]. The benefits were observed in both
SCC and non-SCC (NSCC), with a larger impact on response
in SCC. For this reason, the carboplatin/nab-P regimen could
be considered a chemotherapeutic option in advanced
NSCLC patients, particularly in patients with greater risk of
neurotoxicity, pre-existing hypersensitivity to paclitaxel or
contraindications for standard paclitaxel premedication [I, B].
First-line treatment of SCC
Most individual trials and meta-analyses evaluating ChT options
in the first-line treatment of advanced NSCLC did not report any
differential efficacy in patients with SCC [104]. Therefore,
platinum-based doublets with the addition of a third-generation
cytotoxic agent (gemcitabine, vinorelbine, taxanes) are recom-
mended in advanced SCC patients without major comorbidities
and PS 0–2 [I, A] (Figure 1).
Necitumumab, an immunoglobulin G1 (IgG1) monoclonal
antibody against EGFR, did not demonstrate a significant impact
in first-line treatment of metastatic NSCC when added to cis-
platin/pemetrexed [114]. However, outcomes were different
when necitumumab was combined with different ChT regimens
in SCC. In the SQUIRE trial, the addition of necitumumab to cis-
platin/gemcitabine produced a significant OS improvement
(11.5 versus 9.9 months, HR 0.84, 95% CI 0.74–0.96; P¼ 0.01)
and PFS improvement, with a 1-year survival equal to 48% in the
experimental arm versus 43% in the control arm [115]. In a retro-
spective analysis, the group of patients expressing EGFR (assessed
by IHC) showed an improvement in OS and PFS [mOS
11.7 months versus 10.0 months; HR 0.79, 95% CI 0.69–0.92;
P¼ 0.002; mPFS 5.7 versus 5.5 months, HR 0.84, 95% CI 0.72–
0.92; P¼ 0.018] [116]. Based on these results, due to the limited
clinical improvement, the addition of necitumumab to cisplatin
and gemcitabine has not been adopted as a standard in Europe
for advanced SCC and its use should be carefully evaluated [I, C;
ESMO-MCBS v1.1 score: 1].
First-line treatment of NSCC
Any platinum-based doublets with a third-generation agent
including gemcitabine, vinorelbine or taxanes can be used in
NSCC (Figure 2). The incorporation of pemetrexed and bevaci-
zumab into individual treatment schedules should be considered,
based on the following:
• Pemetrexed-based combination ChT represents a therapeut-
ic option, based on the results of a recent meta-analysis that
showed a slight but significant survival benefit compared
with gemcitabine- or docetaxel-based combinations and of a
pre-planned subgroup analysis of a large randomised phase
III trial [II, A] [117, 118]. Pemetrexed use should be
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restricted to NSCC in any line of treatment in advanced dis-
ease [II, A] [119, 120].
• The survival benefit of carboplatin in combination with
pemetrexed has been investigated in a meta-analysis (ex-
ploratory subgroup analysis); survival benefit for pemetrexed
plus platinum held true for cisplatin-containing regimens
but not for carboplatin-based regimens; however, results
from prospective randomised studies investigating this ques-
tion are not yet available [117]. The combination of carbo-
platin with pemetrexed can be an option in patients with a
contraindication to cisplatin [II, B].
• Findings of two randomised clinical trials revealed that beva-
cizumab improves OS when combined with paclitaxel/car-
boplatin regimens in patients with NSCC and PS 0–1 and,
therefore, may be offered in the absence of contraindications
in eligible patients with advanced NSCC (bevacizumab
should be given until progression) [I, A] [121, 122]. A rand-
omised phase III trial evaluating gemcitabine/cisplatin com-
bination with or without bevacizumab demonstrated an
ORR and modest PFS advantage, but no OS benefit [123].
Two meta-analyses showed a consistent significant improve-
ment in ORR, PFS and OS for the combination of bevacizumab
and platinum-based ChT, compared with platinum-based ChT
alone in eligible patients with NSCC [124, 125]. Bevacizumab
might therefore be considered with platinum-based regimens be-
yond paclitaxel/carboplatin in the absence of contraindications
[II, B]. Treatment with bevacizumab has also shown encouraging
efficacy and acceptable safety in patients with NSCC and asymp-
tomatic, untreated brain metastases [126].
Maintenance
Decision-making about maintenance therapy must take into ac-
count histology, residual toxicity after first-line ChT, response to
platinum doublet, PS and patient preference. Several trials have
investigated the role of maintenance treatment in patients with
good PS (0–1) either as ‘continuation maintenance’ or as ‘switch
maintenance’. ‘Continuation maintenance’ and ‘switch mainten-
ance’ therapies refer to the maintained use of an agent included
in first-line treatment or the introduction of a new agent after
four cycles of platinum-based ChT, respectively. One randomised
phase III switch maintenance trial has reported improvements in
PFS and OS with pemetrexed [120] and erlotinib [127] versus
placebo, following four cycles of platinum-based ChT. In the case
of pemetrexed, this benefit was seen only in patients with NSCC
[I, B]. Furthermore, the phase III IUNO study (maintenance
erlotinib) failed to meet its primary endpoint of OS (HR 1.02;
95% CI 0.85–1.22; P¼ 0.85) [128]. Maintenance treatment with
erlotinib is only recommended for NSCC patients with an EGFR-
sensitising mutation [III, B]. Randomised trials investigating
continuation maintenance have shown an improvement in PFS
and OS. A large phase III randomised trial of continuation main-
tenance with pemetrexed versus placebo after four induction
cycles of cisplatin plus pemetrexed ChT demonstrated a PFS and
OS improvement in patients with a PS 0–1, confirmed at long-
term follow-up [129, 130]. mOS was 13.9 months (95% CI 12.8–
16.0) with pemetrexed and 11.0 months (95% CI 10.0–12.5) with
placebo, with 1- and 2-year survival rates significantly longer for
patients given pemetrexed (58% and 32%, respectively) than for
those given placebo (45% and 21%). Another phase III study
comparing maintenance bevacizumab, with or without peme-
trexed, after first-line induction with bevacizumab, cisplatin and
pemetrexed showed a benefit in PFS for the pemetrexed/bevaci-
zumab combination but no improvement in OS [131], although
a trend towards improved OS was seen when analysing 58% of
events of 253 patients randomised for this study [132]. In the
PointBreak trial, which compared carboplatin/paclitaxel/bevaci-
zumab followed by bevacizumab with carboplatin/pemetrexed/
bevacizumab followed by pemetrexed/bevacizumab, OS was com-
parable in both arms (12.6 versus 13.4 months; HR 1.00; 95% CI
0.86–1.16; P¼ 0.949) [133]. In a phase III trial, it was also shown
that continuation maintenance with gemcitabine significantly
reduces disease progression (mPFS, 3.8 versus 1.9 months; HR
0.56; 95% CI 0.44–0.72) with a non-significant OS improvement
in patients with advanced NSCLC treated with four cycles of cis-
platin/gemcitabine as first-line ChT [I, C] [134]. Continuing
pemetrexed following completion of four cycles of first-line cis-
platin/pemetrexed ChT is, therefore, recommended in patients
with NSCC, in the absence of progression after first-line ChT and
upon recovery from toxicities from the previous treatment [I, A].
Of note, three studies, one employing bevacizumab and the other
two using monoclonal antibodies against EGFR (cetuximab or
necitumumab) administered concomitantly to ChT and further
continued as monotherapy until disease progression, have demon-
strated survival benefits; however, the specific role of the mainten-
ance phase cannot be appreciated in this context [115, 121, 135].
PS 2 and beyond
ChT prolongs survival and improves QoL in NSCLC patients
with PS 2 when compared with BSC [I, A] [136, 137].
A recently published meta-analysis of randomised trials com-
paring the efficacy and safety of platinum-based doublets versus
single-agent regimens in the first-line therapy of PS 2 patients
revealed platinum-based regimens to be superior in terms of
ORR and survival despite an increase in toxicities (mainly haem-
atological) [138]. The superiority of carboplatin-based combina-
tions over monotherapy in PS 2 patients has been identified
within two large phase III trials [137, 139], with an acceptable
toxicity profile. Therefore, platinum-based (preferably carbopla-
tin) doublets should be considered in eligible PS 2 patients [I, A].
Single-agent ChT with gemcitabine, vinorelbine, docetaxel [I, B]
or pemetrexed (restricted to NSCC) [II, B] is an alternative treat-
ment option [139, 140].
All phase III studies with immunotherapies reported until today
excluded patients with PS  2. Reported in abstract form only,
CheckMate 153 included 108 patients with advanced NSCLC and
PS 2 treated with single-agent nivolumab [141]. mOS was
3.9 months and 1-year survival 23%, being lower than observed in
patients with PS 0–1. Toxicities associated with treatment were
comparable between PS 0–1 and PS 2 patients. Interestingly, an im-
provement in patient-reported outcomes was observed for non-
squamous NSCLC patients in the context of this trial. In a
European-based safety phase II trial (CheckMate 171), among 809
patients enrolled, 98 PS 2 patients were treated with nivolumab;
the safety was comparable to the overall population with an mOS
of 5.4 months [142]. In conclusion, insufficient data are available
Annals of Oncology Clinical Practice Guidelines
Volume 29 | Supplement 4 | October 2018 doi:10.1093/annonc/mdy275 | iv203
to date on the use of checkpoint inhibitors for these patients, but
this treatment option can be considered [III, B].
Poor PS (3–4) patients should be offered BSC in the absence of
documented sensitising alterations such as EGFR mutations, ALK
or ROS1 rearrangements or BRAF V600 mutation [III, B].
Elderly patients
In the early 2000s, based on several phase III trials, single-agent
ChT over BSC was established as the standard of care for first-line
therapy of advanced NSCLC patients aged> 70 years [140, 143]. A
recent systematic review identified platinum-based combination
ChT as the preferred option for patients > 70 years of age with PS
0–2 and adequate organ function [144]. Here, data from 13 rando-
mised controlled trials (RCTs) with 1705 patients> 70 years of age
showed that the addition of platinum agents resulted in improve-
ment in OS (HR 0.76; 95% CI 0.69–0.85), PFS (HR 0.76; 95% CI
0.61–0.93) and ORR (RR 1.57; 95% CI 1.32–1.85) compared with
non-platinum containing therapy. Carboplatin was associated with
an OS benefit (HR 0.67; 95% CI 0.59–0.78) whereas cisplatin was
not (HR 0.91; 95% CI 0.77–1.08). Treatment with platinum-based
combinations comes at the expense of more treatment-related mor-
bidity, mainly anaemia, thrombocytopaenia, emesis, diarrhoea and
peripheral neuropathy; this should be weighed against the expected
survival benefit. It is noteworthy that those RCTs that included for-
mal QoL analysis found no difference in QoL between treatment
with platinum-based combinations or single agents in this popula-
tion [137, 145]. Nevertheless, concerns about treatment-related tox-
icity in the elderly population has led to the study of comprehensive
geriatric assessment (CGA) as a selection tool for treatment with ei-
ther platinum-based regimens, single-agent therapy or BSC based
on patient’s fitness or frailty. The sole prospective randomised trial
reported failed to demonstrate an improvement in time to treat-
ment failure and OS for advanced NSCLC patients> 70 years when
treatment (carboplatin doublet, single-agent ChT or BSC) was allo-
cated based on CGA alone or a combination of PS and age. Also, the
incidence of grade 3–4 toxicities was not different between the two
arms in this study [146]. Carboplatin-based doublet ChT is recom-
mended in eligible elderly patients with PS 0–2 and with adequate
organ function [I, A]. For those patients not eligible for doublet
ChT, single-agent ChT remains the standard of care [I, B].
Evidence is accumulating for immune checkpoint inhibitors in
elderly patients with advanced NSCLC. Although no studies dedi-
cated to elderly patients were reported yet, it can be inferred that
ORRs and survival are not different between patients  65 years
and those > 65, based on subgroup analysis of the randomised
second-line trials [63, 147–150]. Of note, no differences in toxicities
were observed [149]. In KEYNOTE-024, comparing first-line pem-
brolizumab with combination ChT in advanced NSCLC patients
whose tumours expressed PD-L1> 50%, half the randomised
patients were> 65 years of age. In the subgroup analysis, the bene-
ficial effect of pembrolizumab was not different between patients
aged  65 years and > 65 years of age (HR 0.61 versus 0.45) [62].
Likewise, in CheckMate 026, comparing nivolumab with combin-
ation ChT in unselected first-line advanced NSCLC patients, there
was no difference in survival outcomes between patients treated
with nivolumab aged  65 years and those > 65 years [66].
Immunotherapy should therefore be considered according to
standard recommendations in elderly patients [III, A].
Second-line treatment of NSCLC without
actionable oncogenic driver
In the few years since benefit was shown with PD-1 blockade in
lung cancers, three PD-1 or PD-L1 therapies have been approved
by the United States Food and Drug Administration (FDA) and
the EMA in the second-line setting.
The three approved therapies in the immunotherapy-naive, se-
cond-line setting include nivolumab, pembrolizumab and atezo-
lizumab. Each has been approved on the basis of phase III studies
demonstrating improved OS in comparison with docetaxel.
Results are summarised below. Overall, there are no major differ-
ences in terms of efficacy or safety among these three therapies to
inform a single optimal choice, and no comparative studies have
been conducted. There are two key distinctions between the three
approved therapies, which can affect choice and use:
1. PD-L1 expression: nivolumab and atezolizumab are
approved in patients with previously treated, advanced
NSCLC irrespective of PD-L1 expression, while pembrolizu-
mab is approved only in patients with PD-L1  1%.
2. Schedule of administration: atezolizumab and pembrolizu-
mab are approved to be given once every three weeks, while
nivolumab is given once every two weeks based on current
EMA approval. Of note, the FDA has recently approved a 4-
weekly schedule for nivolumab.
Overall, any of these three therapies represents reasonable
standard therapy for most patients with advanced, previously
treated, PD-L1-naive NSCLC. Treatment of patients with a his-
tory of autoimmune disease should be considered only with cau-
tion and after discussion of risks/benefits. Because of the risk of
graft rejection, anti-PD-1/PD-L1 agents should be avoided in
patients with solid organ transplantation. For reference, we sum-
marise the key data from the relevant phase III studies here:
• Nivolumab: two phase III studies, CheckMate 017 and
CheckMate 057, have established the effectiveness of nivolu-
mab in the second-line setting [147, 148]. In CheckMate
017, 272 patients with squamous NSCLC were randomised
to nivolumab or docetaxel. OS was significantly improved in
those who received nivolumab (HR 0.59, 95% CI 0.44–0.79,
P < 0.001). In CheckMate 057, 582 patients with non-
squamous NSCLC were randomised to nivolumab or doce-
taxel. OS was significantly improved with nivolumab (HR
0.73, 95% CI 0.59–0.89, P ¼ 0.002). In a recent update of
these studies, 2-year OS favoured nivolumab in both squa-
mous (29% versus 16% with docetaxel) [I, A; ESMO-MCBS
v1.1 score: 5] and non-squamous NSCLC (23% versus 8%)
[I, A; ESMO-MCBS v1.1 score: 5]. Tolerability also favoured
nivolumab, with 10% of patients experiencing grade 3–4
treatment-related AEs compared with 55% with docetaxel.
• Pembrolizumab: The KEYNOTE-010 trial randomised 1034
patients with previously treated NSCLC with PD-L1 expression
on at least 1% of tumour cells to receive pembrolizumab (tested
at two doses, 2 mg/kg or 10 mg/kg, each given every three
weeks) or docetaxel 75 mg/m2 every 3 weeks [63, 151]. OS was
significantly longer for pembrolizumab versus docetaxel (2 mg/
kg, HR 0.71, 95% CI 0.580.88; P< 0.001; 10 mg/kg, HR
0.61, 95% CI 0.490.75; P< 0.001), with a recently reported
2-year OS rate of 14.5% versus 30.1% (2 mg/kg group)
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iv204 | Planchard et al. Volume 29 | Supplement 4 | October 2018
F
ig
u
re
3
.
Tr
ea
tm
en
ta
lg
or
ith
m
fo
rs
ta
ge
IV
N
SC
C
,m
ol
ec
ul
ar
te
st
s
po
si
tiv
e
(A
LK
/B
RA
F/
EG
FR
/R
O
S1
).
a M
C
BS
sc
or
e
fo
rt
he
co
m
bi
na
tio
n
of
be
va
ci
zu
m
ab
w
ith
ge
fit
in
ib
or
er
lo
tin
ib
.
b
N
ot
EM
A
-a
pp
ro
ve
d.
A
LK
,a
na
pl
as
tic
ly
m
ph
om
a
ki
na
se
;E
G
FR
,e
pi
de
rm
al
gr
ow
th
fa
ct
or
re
ce
pt
or
;E
M
A
,E
ur
op
ea
n
M
ed
ic
in
es
A
ge
nc
y;
M
C
BS
,E
SM
O
-M
ag
ni
tu
de
of
C
lin
ic
al
Be
ne
fit
Sc
al
e;
N
SC
C
,n
on
-s
qu
am
ou
s
ce
ll
ca
rc
in
om
a.
Annals of Oncology Clinical Practice Guidelines
Volume 29 | Supplement 4 | October 2018 doi:10.1093/annonc/mdy275 | iv205
F
ig
u
re
4
.
Tr
ea
tm
en
ta
lg
or
ith
m
fo
rs
ta
ge
IV
lu
ng
ca
rc
in
om
a
w
ith
EG
FR
-a
ct
iv
at
in
g
m
ut
at
io
n.
a M
C
BS
sc
or
e
fo
rt
he
co
m
bi
na
tio
n
of
be
va
ci
zu
m
ab
w
ith
ge
fit
in
ib
or
er
lo
tin
ib
.
b
N
ot
EM
A
-a
pp
ro
ve
d.
cf
D
N
A
,c
el
l-f
re
e
D
N
A
;C
hT
,c
he
m
ot
he
ra
py
;E
G
FR
,e
pi
de
rm
al
gr
ow
th
fa
ct
or
re
ce
pt
or
;E
M
A
,E
ur
op
ea
n
M
ed
ic
in
es
A
ge
nc
y;
M
C
BS
,E
SM
O
-M
ag
ni
tu
de
of
C
lin
ic
al
Be
ne
fit
Sc
al
e;
PS
,p
er
fo
rm
an
ce
st
a-
tu
s;
RT
,r
ad
io
th
er
ap
y.
Clinical Practice Guidelines Annals of Oncology
iv206 | Planchard et al. Volume 29 | Supplement 4 | October 2018
[I, A; ESMO-MCBS v1.1 score: 5]. Grade 3–5 treatment-related
AEs were less common with pembrolizumab than with doce-
taxel (13%–16% versus 35%). There was no significant difference
in the efficacy or safety of pembrolizumab at 2 or 10 mg/kg.
• Atezolizumab: The OAK trial [149] evaluated 850 patients
with advanced NSCLC previously treated with one or two
prior lines of ChT, who were randomised to atezolizumab or
docetaxel. OS was significantly improved with atezolizumab
(HR 0.73, 95% CI 0.62–0.87, P<0.001). Tolerability was also
better with atezolizumab, with 15% of patients experiencing
a grade 3–4 treatment-related toxicity compared with 43% of
those treated with docetaxel [I, A; ESMO-MCBS v1.1 score: 5].
There is a general trend across each of the phase III studies in
second-line (nivolumab, pembrolizumab and atezolizumab ver-
sus docetaxel) for enriched efficacy of anti-PD-1/PD-L1 agents in
patients with higher PD-L1 expression compared with those with
no/less PD-L1 expression. However, unselected patients may still
have improved survival and tolerability with anti-PD-1/PD-L1
agents compared with docetaxel [I, A].
Therefore, anti-PD-1/PD-L1 agents are the treatment of choice
for most patients with advanced, previously treated, PD-L1-naive
NSCLC, irrespective of PD-L1 expression [I, A].
Combination ChT regimens failed to show any OS benefit over
single-agent treatments in second line. Single agents improve
disease-related symptoms and OS. Docetaxel has shown improved
efficacy compared with BSC in randomised trials with a significant
improvement in OS in the TAX 320 trial for those patients who
received docetaxel at a dose of 75 mg/m2 every 3 weeks [152, 153].
Similar efficacy, but more favourable tolerability for the weekly
schedule, could be confirmed in randomised trials comparing 3-
weekly to weekly schedules of docetaxel [I, B] [154, 155].
Pemetrexed demonstrated comparable OS to docetaxel in a
randomised phase III trial but had a more favourable toxicity
profile, with lower rates of neutropaenia, alopaecia and gastro-
intestinal events [156]. A retrospective analysis confirmed a pre-
dictive impact of histology with an improved efficacy of
pemetrexed compared with docetaxel in patients with non-
squamous NSCLC (mOS 9.0 versus 8.3 months; HR 0.78; 95% CI
0.61–1.0, P¼ 0.004) [119].
While registration trials of pemetrexed and docetaxel did not
limit therapy to a set number of treatment cycles, second-line
treatment duration should be individualised. Treatment may be
prolonged if disease is controlled and toxicity acceptable [II, B].
Docetaxel and pemetrexed (for NSCC only) are confirmed
treatment options in second-line ChT, with comparable efficacy
[I, B], taking into account that immunotherapy is now the cur-
rent standard second-line systemic therapy and that these agents
have not been formally assessed after checkpoint inhibitors.
In several trials, the combination of antiangiogenic agents with
ChT has been investigated in patients with pretreated advanced
NSCLC. In the REVEL trial, ramucirumab, a vascular endothelial
growth factor receptor 2 (VEGFR2) antibody, in combination
with docetaxel, showed a superior OS (mOS 10.5 versus
9.1 months, HR 0.86; 95% CI 0.75–0.98, P¼ 0.032) and PFS
(mPFS 4.5 versus 3 months, P< 0.0001) compared with doce-
taxel and placebo regardless of histology [ESMO-MCBS v1.1
score: 1] [157]. The main AEs associated with ramucirumab con-
sisted of myelotoxicity, oedema and mucositis. The efficacy of
this combination was also preserved in the poor prognosis group
of patients who did not show any response to first-line ChT
[157, 158]. Nintedanib, an oral angiokinase inhibitor, improved
PFS in combination with docetaxel compared with ChT alone in
the LUME-1 trial (mPFS 3.4 versus 2.7 months, HR 0.79; 95% CI
0.68–0.92; P¼ 0.0019) [159]. A significant prolongation of OS
was observed in the group of patients with adenocarcinoma hist-
ology (mOS 12.6 versus 10.3 months; HR 0.82, 95% CI 0.7–0.99,
P¼ 0.0359). Gastrointestinal events and transient elevation of
liver enzymes were the most frequent AEs associated with ninte-
danib. However, the QoL analyses did not show any impact on
QoL measurements for this combination. Again, improved effi-
cacy was seen in the poor prognostic group of patients with non-
responding or fast progressing tumours [159, 160]. The efficacy
of the combination of antiangiogenic agents and ChT was con-
firmed in the ULTIMATE trial, which showed prolongation of
PFS for the combination of weekly paclitaxel and bi-weekly beva-
cizumab compared with docetaxel (mPFS 5.4 versus 3.9 months,
HR 0.62; 95% CI 0.44–0.86; P¼ 0.005) with no difference in OS
[161]. The combination of ramucirumab and docetaxel repre-
sents a treatment option for patients with NSCLC progressing
after previous ChT or immunotherapy, with PS 0–2 [I, B]. The
combination of nintedanib and docetaxel represents a treatment
option for patients with adenocarcinoma progressing after previ-
ous ChT or immunotherapy [II, B]. Combination of paclitaxel
and bevacizumab is another treatment option [I, C; not EMA-
approved].
Erlotinib represents a potential second-/third-line treatment
option, in particular for patients not suitable for immunotherapy
or second-line ChT in unknown EGFR status or EGFR wild-type
(WT) tumours [II, C]. Erlotinib has shown superiority in OS
compared with BSC in pretreated patients not eligible for further
ChT (mOS 6.7 versus 4.7 months, HR 0.7; 95% CI 0.58–0.85,
P< 0.001) [162]. In two additional trials, comparable efficacy of
erlotinib and ChT has been reported for patients with refractory
NSCLC (progression during first-line platinum-based ChT) or in
second-/third-line therapy [163, 164].
In the recent years, a growing number of reports revealed an in-
ferior efficacy of EGFR TKIs in pretreated patients with EGFR
WT tumours compared with ChT [165]. In a meta-analysis sum-
marising the results of 6 randomised trials with 900 patients, PFS
for EGFR TKI was significantly inferior to ChT in the group of
patients with EGFR WT tumours (HR 1.37, 95% CI 1.20–1.56,
P< 0.00001). However, these results did not translate into an OS
difference (HR 1.02, 95% CI 0.87–12, P¼ 0.81) [166]. An add-
itional analysis of the Biomarkers France study reported a signifi-
cant improvement in PFS or OS for second-line ChT compared
with second-line EGFR TKI in 1278 patients with pretreated
NSCLC (PFS 4.3 versus 2.83 months, HR 0.66, 95% CI 0.57–0.77,
OS 8.39 versus 4.99 months, HR 0.7, 95% CI 0.59–0.83,
P< 0.0001) [167].
In patients with advanced SCC, afatinib was investigated versus
erlotinib in the LUX-Lung 8 trial. PFS and OS were improved in fa-
vour of afatinib (PFS 2.4 versus 1.9 months, HR 0.82, 95% CI 0.68–
1.00, P¼ 0.041; OS 7.9 versus 6.8 months, HR 0.81, 95% CI 0.69–
0.95, P¼ 0.0077) [168]. Afatinib was associated with improved pre-
specified disease-related symptoms and health-related QoL [169].
Afatinib could be a therapeutic option in patients with
advanced SCC with PS 0–2 unfit for ChT or immunotherapy,
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progressing on or after ChT with unknown EGFR status or EGFR
WT [I, C; ESMO-MCBS v1.1 score: 2].
In conclusion, patients clinically or radiologically progressing
after first-line therapy with PS 0–2 should be offered second-line
therapy, irrespective of administration of maintenance treatment
[I, A]. So far, no prospective trials have determined the best
second-line therapy following failure of first-line treatment with
pembrolizumab; however, according to the first-line trial results,
the preferred recommendation would be a platinum-based ChT,
as discussed above [V, B] [62].
Treatment of EGFR-mutated NSCLC
First-line treatment. EGFR mutation is the best established
oncogenic target for management of advanced stage NSCLC
[170, 171]. The predictive power of EGFR mutation is confirmed
in multiple randomised phase III studies comparing first- (erloti-
nib or gefitinib) or second-generation (afatinib) EGFR TKIs with
standard platinum-based ChT [I, A] [172–177]. The benefit of
improvement in ORR and PFS is consistent across all age groups,
genders, smoking status and PS. Notably, none of the above stud-
ies have shown any benefit in OS for an EGFR TKI over
platinum-based ChT, likely due to the high level of crossover.
EGFR TKIs represent the standard of care as first-line treatment
for advanced EGFR-mutated NSCLC [I, A] (Figures 3 and 4).
Patients with PS 3–4 may also be offered an EGFR TKI as they are
likely to receive a similar clinical benefit as patients with good PS
[III, A] [178]. Patients who have benefited from EGFR TKI treat-
ment may continue to receive the same therapy beyond initial
radiological progression as long as they are clinically stable [II, A]
[179]. Patients with localised distant progression and ongoing
systemic control, continuation of treatment with EGFR TKI in
combination with local treatment of progressing metastatic sites
may be considered [III, B]. Continuous use of EGFR TKI in com-
bination with ChT is not recommended as it was not associated
with PFS improvement [I, A] and showed a detrimental effect on
OS [II, B] [180].
The choice between first- and second-generation EGFR TKIs
was investigated in two randomised studies. LUX-Lung 7 is a
randomised phase IIB study that compares afatinib with gefitinib
[181]. The study reported similar tumour ORR and a modest dif-
ference in PFS (mPFS 11.0 versus 10.9 months; HR 0.73, 95% CI
0.57–0.95, P¼ 0.0165). The other co-primary endpoint for this
study was OS and was not statistically different (mOS 27.9 versus
24.5 months; HR 0.86, 95% CI 0.66–1.12, P¼ 0.258) [182]. More
specifically, there was no difference in OS in patients with EGFR
exon 19 mutation, which is contrary to the earlier claim of benefit
in this subgroup from the pooled analysis of LUX-Lung 3 and
LUX-Lung 6 studies [183].
ARCHER 1050 is a randomised phase III study that compares
dacomitinib with gefitinib in stage IV EGFR-mutated lung cancer
patients without CNS metastasis [184, 185]. The study reported
significant improvement in PFS (mPFS 14.7 versus 9.2 months;
HR 0.59, 95% CI 0.47–0.74, P< 0.0001). The mOS was
34.1 months with dacomitinib versus 26.8 months with gefitinib
(HR 0.76, 95% CI 0.58–0.993, P¼ 0.04). The OS probabilities at
30 months were 56.2% and 46.3% with dacomitinib and gefitinib,
respectively. Both afatinib and dacomitinib are associated with
higher incidence of grade 3 skin and gastrointestinal toxicity and
a significant proportion of patients require dose reduction.
Erlotinib, gefitinib and afatinib are recommended as first-line
therapy in patients with advanced NSCLC who have active sensi-
tising EGFR mutations, regardless of their PS [I, A]. Dacomitinib
will be added to the list when the drug is approved by regulatory
agencies, the United States FDA and the EMA [I, A; not EMA-
approved]. There is no consensus preferring any of the three cur-
rently available first-line EGFR TKIs over others [IV, C].
Osimertinib is a third-generation EGFR TKI that targets both
sensitising EGFR mutation and the resistant exon 20 T790M mu-
tation [186]. The drug was compared with a standard first-
generation EGFR TKI (gefitinib or erlotinib) in the FLAURA
phase III study [187]. Significant improvement in PFS was
observed (mPFS 18.9 versus 10.2 months; HR 0.46, 95% CI 0.37–
0.57, P< 0.0001). More importantly, a similar degree of improve-
ment was observed in the subgroup of patients with CNS metas-
tasis (mPFS 15.2 versus 9.6 months; HR 0.47, 95% CI 0.30–0.74,
P¼ 0.0009). OS data were immature, while authors reported
an HR of 0.63, which was not statistically significant. First-line
osimertinib is now considered one of the options for NSCLC
patients with sensitising EGFR mutations [I, A; MBCS score v1.1
score: 4].
The combination of ChT with gefitinib, at progression with
gefitinib, has not shown any clinical benefit (IMPRESS Trial)
[188]. The NEJ009 trial is the first phase III study that evaluated
the efficacy of a combination of EGFR TKI (gefitinib) and plat-
inum doublet ChT (carboplatin/pemetrexed) in untreated
advanced NSCLC patients with EGFR mutations [189].
Carboplatin/pemetrexed/gefitinib demonstrated significantly
better PFS (mPFS: 20.9 versus 11.2 months, HR 0.49, 95% CI
0.39–0.62) and OS (mOS: 52.2 versus 38.8 months, HR 0.69, 95%
CI 0.52–0.92) compared with gefitinib, in advanced EGFR-
mutated NSCLC, representing a first-line therapy option [I, B;
not EMA-approved].
The combination of EGFR TKI and antiangiogenesis was first
investigated in Japan. A randomised phase II study compared the
combination of erlotinib and bevacizumab with erlotinib alone
as first-line therapy for patients with EGFR-mutant NSCLC. Seto
et al. reported mPFS of 16.4 and 9.8 months (HR 0.52, 95% CI
0.35–0.76), respectively [II, A] [190, 191]. However, the signifi-
cant difference of PFS did not translate into a difference of OS be-
tween these treatments (mOS: 47 versus 47.4 months). A similar
PFS was described in a European phase II trial that also evaluated
the combination of erlotinib and bevacizumab, which was deter-
mined to be suitable as a front-line treatment option in EGFR-
mutated NSCLC [III, B] [192]. A phase III trial (NEJ026) com-
paring bevacizumab/erlotinib to erlotinib in this patient popula-
tion reported encouraging interim analysis results with
significant benefit on PFS (mPFS 16.9 versus 13.3 months, HR
0.60, 95% CI 0.41–0.87); survival results are pending [II, A]
[193]. While active research is ongoing, the EMA has approved
the use of the combination of erlotinib and bevacizumab
[ESMO-MCBS v1.1 score: 3]. Erlotinib/bevacizumab represents
a front-line treatment option in EGFR-mutated tumours [II, B].
Beyond first-line treatment. Almost all patients who benefit from
EGFR TKIs will eventually develop clinical resistance. About half
of the resistance is explained by the acquired EGFR exon 20
T790M mutations [194]. Osimertinib and several other third-
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generation EGFR TKIs were developed targeting the T790M mu-
tation. To date, the only approved medication for patients with
T790M mutation is osimertinib. AURA3 is a randomised phase
III study that compared osimertinib with pemetrexed/platinum
in patients with proven T790M mutation at time of progression
on first-/second-generation EGFR TKI [195]. Tumour ORR was
71% and 31%, respectively (HR 5.39, 95% CI 3.46–8.48,
P< 0.001). The primary endpoint of PFS was also significantly
different (mPFS 10.2 versus 4.4 months; HR 0.30, 95% CI 0.23–
0.41, P< 0.0001). Osimertinib also showed a significantly
longer CNS PFS (11.7 months) and higher CNS ORR (70%, 95%
CI 51–85) compared with ChT (CNS PFS 5.6 months, CNS ORR
31%, 95% CI 11–59) in patients with CNS metastases at baseline
[196]. The probability of experiencing a CNS progression event
was lower for osimertinib than for ChT at both 3 months (2.7%
versus 8.2%, respectively) and 6 months (11.5% versus 28.2%, re-
spectively). This study has established a new paradigm: all
patients with clinical resistance to first-/second-generation EGFR
TKIs should be tested for the presence of T790M mutation and
osimertinib should be offered as standard treatment for patients
who test positive [I, A; ESMO-MCBS v1.1 score: 4].
Molecular mechanisms of resistance to EGFR TKIs were com-
plex and heterogenous in patients without T790M mutation.
These include MET amplification, HER2 amplification, PIK3CA
alternations, BRAF mutation, KRAS mutation and small cell
transformation. The current standard in this scenario is
platinum-based doublet ChT [I, A] and the expected ORR and
PFS are 31% and 5.4 months, respectively [188], and should be
considered as a therapeutic option in patients with EGFR-
mutated tumour, PS 0–1, in absence of contraindications to use
of immunotherapy after targeted therapies have been exploited
[III, A; not EMA-approved] [97].
Treatment of ALK-rearranged NSCLC
First-line treatment. The anti-tumour activity of crizotinib was
initially demonstrated in two multicentre single-arm studies,
with significant ORR and PFS advantages, as well as a survival ad-
vantage, compared with other treatment options [197, 198]. The
phase III study, PROFILE 1014, compared crizotinib with
platinum–pemetrexed (without maintenance pemetrexed) as
first-line treatment in ALK-rearranged advanced NSCLC. It dem-
onstrated a significantly longer PFS (mPFS 10.9 versus
7.0 months; HR 0.45; 95% CI 0.35–0.60; P< 0.001) and higher
ORR with crizotinib compared with ChT [199]. First-line treat-
ment with crizotinib is a treatment option for patients with ALK-
rearranged NSCLC [I, A; ESMO-MBCS v1.1 score: 4] (Figures 3
and 5).
Ceritinib and alectinib are second-generation ALK inhibitors
that have shown robust antitumour efficacy, along with intracra-
nial activity, in patients with ALK-rearranged NSCLC. The
ASCEND-4 trial compared ceritinib (750 mg/day) with
platinum-based ChT (cisplatin or carboplatin plus pemetrexed
followed by maintenance pemetrexed) in untreated advanced
ALK-rearranged non-squamous NSCLC [200]. Overall, ceritinib
improved ORR over ChT: 72.5% (95% CI 65.5–78.7) compared
with 26.7% (95% CI 20.5–33.7). mPFS was 16.6 months (95% CI
12.6–27.2) with ceritinib versus 8.1 months (95% CI 5.8–11.1)
with ChT (HR 0.55, 95% CI 0.42–0.73, P< 0.01). At baseline, 59
patients in the ceritinib arm and 62 patients in the ChT arm had
CNS metastasis. Among them, the intracranial ORR by RECIST
was 72.7% (95% CI 49.8–89.3) with ceritinib versus 27.3% (95%
CI 10.7–50.2) with ChT. In patients without baseline brain CNS
metastasis, the mPFS with ceritinib was 26.3 months (95% CI
15.4–27.7), versus 8.3 months (95% CI 6.0–13.7) in the ChT arm.
The most common AEs (all grades) in the ceritinib group were
diarrhoea (85%), nausea (69%), vomiting (66%) and an increase
in alanine aminotransferase (ALT, 60%) [ESMO-MCBS v1.1
score: 4]. Considering the safety profile of ceritinib, the influence
of food on its oral bioavailability and the fact that food may im-
prove gastrointestinal tolerability, a trial was conducted with a
lower dose of ceritinib taken with a low-fat meal (ASCEND-8)
[201]. A 450 mg dose of ceritinib taken once daily with food pro-
vides similar systemic exposure as the currently approved daily
dose of 750 mg in a fasted state, and preliminary safety results
demonstrated a reduction of the gastrointestinal toxicities when
compared with the 750 mg fasted dose. These results suggest this
dosing regimen as an alternative to the ceritinib 750 mg fasted
dose [III, B].
The efficacy of alectinib was tested in a phase III head-to-head
trial comparing this molecule [300 mg twice daily (b.i.d.)] with
crizotinib (250 mg b.i.d.) in ALK TKI-naive ALK-rearranged
advanced NSCLC Japanese patients (J-ALEX trial), demonstrat-
ing the superiority of alectinib as an initial targeted treatment
[202]. The PFS HR of the alectinib arm compared with the crizo-
tinib arm was 0.34 (95% CI 0.17–0.70, P< 0.0001). mPFS was
not reached [95% CI 20.3–not evaluable (NE)] in the alectinib
arm, while it was 10.2 months (95% CI 8.2–12.0) in the crizotinib
arm. A similar global trial in ALK-rearranged treatment-naive
patients was conducted (ALEX trial). Patients were randomised
to receive either alectinib (600 mg b.i.d.) or crizotinib (250 mg
b.i.d.) [53]. The investigator-assessed mPFS with alectinib was
34.8 (95% CI 17.7–not reached), compared with 10.9 months
(95% CI 9.1–12.9) with crizotinib [203]. PFS assessed by the in-
dependent review committee was also significantly longer with
alectinib than with crizotinib (mPFS 25.7 months; 95% CI 19.9–
NE versus 10.4 months; 95% CI 7.7–14.6, respectively). In
patients with baseline CNS metastases, mPFS was 27.7 months
for alectinib versus 7.4 months for crizotinib. The time to CNS
progression was significantly longer with alectinib than with cri-
zotinib (cause-specific HR 0.16, 95% CI 0.10–0.28, P< 0.001).
The mOS was not estimable in either group. Grade 3–5 AEs were
less frequent with alectinib (41% versus 50% with crizotinib)
[ESMO-MCBS v1.1 score: 4]. In patients with CNS involvement,
front-line use of ALK TKIs is effective, and alectinib [III, A] or
ceritinib [IV, B] are recommended. While ceritinib represents a
better treatment strategy than ChT [I, B] and presumably crizoti-
nib [IV, B], alectinib represents a better treatment option than
ChT [III, A] and crizotinib [I, A].
Beyond first-line treatment. The benefit of crizotinib over
second-line ChT in TKI-naive patients with previously treated
ALK-rearranged NSCLC was confirmed in the phase III
PROFILE 1007, with better ORR and PFS [204]. The mPFS was
7.7 months (95% CI 6.0–8.8) in the crizotinib group, compared
with 3.0 months (95% CI 2.6–4.3) in the ChT group. Any patient
with NSCLC harbouring an ALK fusion should receive crizotinib
as next-line therapy, if not received previously [I, A]. Despite
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improved outcome in patients with tumours harbouring ALK
rearrangements and treated with crizotinib (mainly in first line),
all patients will eventually experience disease progression
through primary or acquired resistance. Furthermore, crizotinib
penetration into the cerebrospinal fluid (CSF) is negligible, and
this pharmacological limitation is extremely relevant in treat-
ment decisions, taking into account the high propensity of ALK-
rearranged NSCLC to metastasise to the brain [205]. Ceritinib
(ASCEND-5) and alectinib (ALUR) were compared with ChT in
patients with ALK-positive NSCLC previously treated with crizo-
tinib and ChT [206, 207]. Both trials showed a significant im-
provement in mPFS compared with ChT (5.4 months, 95% CI
4.1–6.9 for ceritinib versus 1.6 months, 95% CI 1.4–2.8 for ChT;
HR 0.49, 95% CI 0.36–0.6, P< 0.0001 and 9.6 months, 95% CI
6.9–12.2 for alectinib versus 1.4 months, 95% CI 1.3–1.6 for ChT;
HR 0.15, 95% CI 0.08–0.29; P< 0.001). CNS ORR was 54.2%
and 35% with alectinib or ceritinib, respectively, versus 0% or 5%
with ChT in the ALUR and ASCEND-5 trials, respectively [206–
208]. Based on this data, ceritinib and alectinib are recommended
in patients with ALK-positive advanced NSCLC who progress on
treatment with or are intolerant to crizotinib [I, A; ESMO-MBCS
v1.1 score: 4].
In ALK-rearranged patients progressing on crizotinib with
CNS progression, treatment with next-generation ALK TKIs,
such as alectinib or ceritinib, is recommended [I, A]. The next-
generation ALK inhibitors, such as brigatinib or lorlatinib, have a
wider coverage of ALK resistance mutations, and sequential ther-
apy with these ALK inhibitors is the preferred treatment ap-
proach in crizotinib-resistant and/or the second generation-
resistant populations. The ALTA trial evaluated the brigatinib in
crizotinib-resistant ALK-rearranged NSCLC patients. Patients
were randomised (1:1) to receive oral brigatinib 90 mg once daily
(arm A) or 180 mg once daily with a 7-day run-in at 90 mg (arm
B) [209]. The ORR was 46% (arm A) and 55% (arm B) and mPFS
was 9.2 months in arm A and 15.6 months in arm B. mOS was not
reached in arm A and was 27.6 months in arm B. CNS ORRs were
50% and 67% in arms A and B, respectively. In results from a
phase I study, lorlatinib demonstrated significant activity report-
ing ORRs of 46% and 42% among ALK-rearranged patients pre-
treated with one or with two or more ALK TKIs, respectively,
including patients with CNS metastases at baseline (intracranial
ORR 42%) [210]. A phase II study at the recommended dose
(100 mg once a day) is demonstrating 69% RR in crizotinib pre-
treated patients and 39% after two or more previous ALK TKIs
[211]. Of interest, in patients previously treated with one or more
second-generation ALK TKIs, a higher proportion of patients
harbouring an ALK secondary mutation responded to treatment
with lorlatinib compared to those without detectable ALK muta-
tions (ORR: 61% versus 26%) [212]. Lorlatinib and brigatinib
are in phase III testing to investigate whether upfront treatment
with the next generation can further improve clinical outcomes
for patients with advanced ALK-rearranged NSCLC compared
with crizotinib treatment [213, 214]. At the first interim analysis,
brigatinib was shown to improve PFS compared with crizotinib
(HR 0.49; 95% CI 0.330.74; P< 0.001) [I, B, not EMA
approved] [215]. In patients with baseline CNS metastases, intra-
cranial objective response rate was 78% for brigatinib versus 29%
for crizotinib. In patients who progress after a second-generation
ALK TKI, the next-generation ALK inhibitors such as brigatinib
or lorlatinib are recommended if available [III, B]. They are cur-
rently not approved by the EMA.
Treatment of ROS1-rearranged NSCLC
On the basis of the available preclinical data, the phase I
PROFILE 1001 study of crizotinib was amended to include
patients with ROS1-rearranged NSCLC in the expansion cohort
[216]. Among 50 patients with ROS1-rearranged NSCLC in this
trial cohort, the ORR to crizotinib was 72%, with a disease con-
trol rate equal to 90% and an mPFS of 19.2 months. In a pro-
spective French phase II study and in the retrospective EUROS1
study of crizotinib for ROS1-rearranged NSCLC, mPFS was 10
and 9.1 months and ORR was 72% and 80%, respectively, al-
though both of these studies enrolled only approximately 30
patients [217, 218]. In a larger East Asian phase II study of crizoti-
nib, the mPFS among 127 patients with ROS1-rearranged lung
cancer was 13.4 months [219]. Each study included patients who
had received varying numbers of prior lines of systemic therapy,
although for all of these patients, crizotinib remained the first
ROS1-directed TKI. Single-agent crizotinib is recommended in
the first-line setting or as second line in patients with stage IV
NSCLC with ROS1 rearrangement [III, A; ESMO-MBCS v1.1
score: 3] (Figures 3 and 6). If patients have received crizotinib in
the first-line setting, then they may be offered platinum-based
ChT therapy in the second-line setting [IV, A].
Ceritinib is a potent and selective ALK inhibitor that also
inhibits ROS1. In a Korean phase II study, 32 patients with
ROS1-rearranged advanced NSCLC were treated with ceritinib,
750 mg daily [220]. Among crizotinib-naive patients, the ORR
was 67%, with a disease control rate of 87%. The mPFS was
9.3 months for the entire cohort and reached 19.3 months for
crizotinib-naive patients. Of note, in those two patients who had
received prior crizotinib, no clinical response was observed.
Ceritinib might be considered in crizotinib-naive patients but is
currently not approved by the EMA [III, C].
Brigatinib, lorlatinib and entrectinib also have a potential anti-
ROS1 activity on the basis of preclinical studies and limited phase
I/II encouraging clinical data [221].
Treatment of BRAF-mutated NSCLC
The most common BRAF mutation, V600E (Val600Glu), is
observed in 1%–2% of lung adenocarcinomas [222–224], more
frequently in patients with smoking history. In a retrospective
multicentre cohort study in Europe, patients with advanced
BRAF-mutant lung cancer received treatment with either vemur-
afenib (n¼ 29), dabrafenib (n¼ 9) or sorafenib (n¼ 1) [225]. Of
the BRAF mutations, 83% were BRAF V600E. The ORR was 53%
and the PFS and OS were 5 and 10.8 months, respectively.
In a vemurafenib basket trial (VE-BASKET), patients with vari-
ous BRAF V600 mutation-positive non-melanoma tumours were
enrolled in six prespecified cancer cohorts, including an NSCLC
cohort with 20 patients [226]. A total of 19 NSCLC patients were
evaluable for response. Overall, one patient was treatment-naive
and 50% and 45% of patients received one or two or more lines of
therapy before study inclusion, respectively. The ORR, mPFS and
mOS were 42%, 7.3 months and not yet reached, respectively.
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A prospective multicentre multicohort phase II study of dabra-
fenib monotherapy (cohort A), or combination therapy with a
MEK inhibitor (trametinib) (cohort B, beyond first-line and co-
hort C in first-line treatment) in patients with BRAF V600E-mu-
tant metastatic NSCLC (BRF113928) was reported. With
dabrafenib monotherapy (cohort A, n¼ 78), the ORR was 33%
and mPFS and median duration of response (mDoR) were 5.5
and 9.6 months, respectively [227]. With combination dabrafe-
nib and trametinib in pretreated patients (cohort B, n¼ 57), the
ORR was 66% and mPFS and mDoR were 10.2 and 9.8 months,
respectively [228, 229]. With combination dabrafenib and trame-
tinib therapy in unpretreated patients (cohort C, n¼ 36), the
ORR was 64% and mPFS and DoR were 10.9 and 10.4 months,
respectively [230]. The mOS was 24.6 months and half of the
patients were still alive at two years from treatment beginning.
The EMA and the United States FDA have approved dabrafenib
in combination with trametinib for the treatment of patients
with BRAF V600 mutation-positive advanced or metastatic
NSCLC. BRAF/MEK inhibition using dabrafenib with trametinib
is recommended in patients with BRAF inhibitor naive, stage IV
NSCLC with BRAF V600E mutation [III, A; ESMO-MBCS v1.1
score: 2] (Figures 3 and 7). If patients have received BRAF/MEK
inhibition in the first-line setting, then they may be offered
platinum-based ChT in the second-line setting [IV, A].
Treatment of NSCLC with other actionable
oncogenic drivers
Several other molecular targets have been identified harbouring
somatic variants with therapeutic potential, including RET,
MET, HER2 and NTRK.
RET fusions are found in 1%–2% of NSCLC and tend to be
mutually exclusive to other lung cancer drivers [231, 232].
Although RET-selective inhibitors have not yet been developed,
several multitarget agents with anti-RET activity have been eval-
uated in preclinical models and clinical trials. The activity of mul-
tikinase inhibitors (cabozantinib, vandetanib, sunitinib,
sorafenib, alectinib, lenvatinib, nintedanib, ponatinib, regorafe-
nib) in patients with RET-rearranged NSCLC (ORR 16%–47%
and mPFS 2.3–7.3 months) is clearly inferior to the responses and
survival outcomes seen with selective TKIs in other oncogene-
addicted NSCLC models [233–236]. These studies are small and
subject to selection bias and results of heterogeneous benefit [III,
C]. Further studies are needed to confirm the benefit of current
treatments as well as the development of more specific inhibitors
(i.e: BLU-667, LOXO-292) [237]. Targeting RET is not currently
routinely recommended and recruitment into open trials is
encouraged [III, C].
Somatic dysregulation at MET occurs through a number of dif-
ferent non-exclusive mechanisms in NSCLC including overex-
pression, amplification, mutation and gene-rearrangement.
Previous trials aimed at targeting MET overexpression (e.g. onar-
tuzumab or tivantinib) have failed, and as the relationship be-
tween expression and genomics is now better understood, focus
has shifted to targeting genomic variants [238–240]. Two major
MET variants may play a key role as NSCLC oncogenic drivers:
MET exon 14 variants (METex14) and MET amplification. MET
amplification can occur as either acquired (as a resistance mech-
anism to EGFR TKI therapy) or de novo. While a promising
target, targeting MET dysregulation by MET amplification is not
currently routinely recommended and recruitment into open tri-
als is encouraged [III, C]. METex14 mutations are similarly as
common as ALK rearrangements, occurring in 3%–4% of
NSCLC. They are more frequently but not exclusively identified
in adenocarcinoma and sarcomatoid carcinoma histological sub-
types (especially those with an adenocarcinoma component),
observed in current, ex- and never-smokers, more frequently
observed in older than in younger patients. METex14 mutations
are extremely diverse and result in aberrant splicing and exon 14
skipping, resulting in loss of the MET Y1003 c-Cbl binding site
and reduced MET degradation, detectable as increased expression
by IHC. Moreover, METex14 mutations are mutually exclusive to
other drivers (EGFR, ALK, BRAF), further reinforcing MET status
as an oncogenic driver, more often encountered in smokers.
Multiple case series and cohorts have now demonstrated durable
ORRs with MET-targeting TKIs including crizotinib, capmatinib
and cabozantinib in METex14 patients, with the PROFILE 1001
trial METex14 cohort reporting an ORR of 44% and a global retro-
spective series demonstrating a PFS of 7 months, both with crizoti-
nib [241, 242]. A variety of MET-directed TKIs are undergoing
development against this target. For METex14 variants, while evi-
dence of benefit is stronger, recruitment into open trials is encour-
aged [III, C]. Crizotinib has demonstrated potential clinical
efficacy that needs to be confirmed [III, C].
HER2 dysregulation is another promising target for advanced
NSCLC and is abrogated via different mechanisms including
exon 20 mutations, transmembrane domain mutations, amplifi-
cation and protein overexpression. Mutations in exon 20 were
the first HER2 mutations described and occur in 1%–5% of
patients, over-represented in young patients, never-smokers,
females, patients without ethnic clustering and typically in
adenocarcinomas [243]. Such mutations are analogous to EGFR
exon 20 insertions, being mutually exclusive to other oncogenic
drivers, and are usually 3–12 bp in-frame insertions between
codons 775–881, the most common being the YVMA insertion at
codon 775. HER2 insertions are typically resistant to HER-target-
ing TKIs afatinib, dacomitinib and neratinib [244, 245], although
some specific genotypes, e.g. those resulting in Gly770 insertion,
may retain sensitivity [246]. Afatinib and poziotinib have dem-
onstrated some activity in HER2-mutated NSCLC in small series
[247, 248]. More recently, targeting HER2 mutation with ado-
trastuzumab emtansine (TDM-1) has shown promise with two
cohorts demonstrating responses including mutants with no
copy-number change [249]. Abnormal gene copy-number is also
identified at HER2, although is typically polysomy, with HER2
exon 20 insertions and amplification usually mutually exclusive
[243]. Targeting HER2 amplification or protein expression with
trastuzumab monotherapy has not consistently demonstrated
benefit, but may have a role in HER2-mutant NSCLC, although
data are usually based on cases confounded by concurrent ChT
and variable HER2 expression. The antibody–drug conjugate
TDM-1 has shown very modest activity in HER2-overexpressing
NSCLC [250]. Rarer HER2 variants include transmembrane do-
main mutations (e.g. V659, G660) that have reported sensitivity
to afatinib and TDM-1 [251]. Nevertheless, given the paucity
of robust data, targeting HER2 dysregulation is not currently
recommended and recruitment into open trials is encouraged
[III, C].
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Table 4. Summary of recommendations
Diagnosis
• Bronchoscopy is a technique ideally suited to central lesions and can be used with bronchial washing, brushing, bronchial and transbronchial biopsy
• EBUS and/or EUS allows evaluation of regional lymph nodes
• Transthoracic fine needle aspiration and/or core biopsy, passing a needle through the parenchyma under imaging guidance (typically CT), is indicated in
case of mid to peripheral lesions
• In presence of a pleural effusion, thoracentesis could represent both a diagnostic tool and a palliative treatment
• More invasive, surgical approaches (mediastinoscopy, mediastinotomy, thoracoscopy etc.) in the diagnostic workup can be considered when the
previously described techniques cannot allow for an accurate diagnosis
• With systematic collaboration and constant communication between pathologists and procedure performers, diagnostic yields will be significantly
greater than with blind biopsies
Pathology/molecular biology
• Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow for individual treatment decisions
• Pathological diagnosis should be made according to the 2015 WHO classification of lung tumours
• Specific subtyping of all NSCLCs is necessary for therapeutic decision making and should be carried out wherever possible. IHC stains should be used to re-
duce the NSCLC-NOS rate to fewer than 10% of cases diagnosed [IV, A]
• EGFR mutation status should be systematically analysed in advanced NSCC [I, A]. Test methodology should have adequate coverage of mutations in exons
18–21, including those associated with resistance to some therapies [III, B]. At a minimum, when resources or material are limited, the most common acti-
vating mutations (exon 19 deletion, exon 21 L858R point mutation) should be determined [I, A]
• The availability of TKIs effective against T790M-mutant recurrent disease makes T790M testing on disease relapse mandatory [I, A]
• All patients with a negative cfDNA blood test still require tissue biopsy [II, A]
• Testing for ALK rearrangement should be systematically carried out in advanced non-squamous NSCLC [I, A]
• Detection of the ALK translocation by FISH remains a standard, but IHC with high-performance ALK antibodies and validated assays may be used for
screening [III, A] and have recently been accepted as an equivalent alternative to FISH for ALK testing
• Testing for ROS1 rearrangement should be systematically carried out in advanced NSCLC [III, A]. Detection of the ROS1 translocation by FISH remains a
standard; IHC may be used as a screening approach [IV, A]
• BRAF V600 mutation status should be systematically analysed in advanced NSCLC for the prescription of BRAF/MEK inhibitors [II, A]
• Molecular EGFR and ALK testing are not recommended in patients with a confident diagnosis of SCC, except in unusual cases, e.g. never/former light smok-
ers or long-time ex-smokers [IV, A]
• If available, multiplex platforms (NGS) for molecular testing are preferable [III, A]. Whatever testing modality is used, it is mandatory that adequate internal
validation and quality control measures are in place and that laboratories participate in, and perform adequately in, external quality assurance schemes for
each biomarker test [III, A]
• PD-L1 IHC should be systematically determined in advanced NSCLC [I, A]
• Testing is required for pembrolizumab therapy but may also be informative when nivolumab or atezolizumab are used [I, A]
Staging and risk assessment
• A complete history including a precise smoking history and comorbidities, weight loss, PS and physical examination must be recorded
• Laboratory: standard tests including routine haematology, renal and hepatic functions and bone biochemistry tests are required
• Routine use of serum tumour markers, such as CEA, is not recommended [IV, B]
• Contrast-enhanced CT scan of the chest and upper abdomen including the liver and the adrenal glands should be carried out at diagnosis
• Imaging of CNS should be considered at diagnosis for all patients with metastatic disease [IV, B] and is required for patients with neurological symptoms or
signs [IV, A]. MRI is more sensitive than CT scan [III, B]
• If bone metastases are clinically suspected, bone imaging is required [IV, B]
• Bone scan or PET, ideally coupled with CT, can be used for detection of bone metastasis [IV, B]. PET-CT is the most sensitive modality in detecting bone
metastasis [II, B]
• NSCLC is staged according to the UICC system (8th edition) and is grouped into the stage categories shown in Tables 2 and 3
• In the presence of a solitary metastatic site on imaging studies, efforts should be made to obtain a cytological or histological confirmation of stage IV dis-
ease [IV, A]
• Response evaluation is recommended after two to three cycles of ChT or immunotherapy, using the same initial radiographic investigation that demon-
strated tumour lesions [IV, B]. The same procedure and timing (every 6–9 weeks) should be applied for the response evaluation in patients treated with tar-
geted therapies and/or immunotherapy [IV, B]. Follow-up with PET is not routinely recommended, due to its high sensitivity and relatively low specificity
[IV, C]
• Measurements and response assessment should follow RECIST v1.1 [IV, A]. The adequacy of RECIST in evaluating the response to EGFR or ALK TKI in respect-
ive genetically driven NSCLC is debatable [IV, B]
• In the case of immune checkpoint inhibitor therapy, RECIST should be used, although irRECIST, iRECIST, imRECIST may have a role in the overall assessment
of therapy [IV, B]
Management of advanced/metastatic disease
• The treatment strategy should consider the histology, molecular pathology, age, PS, comorbidities and the patient’s preferences
• Systemic therapy should be offered to all stage IV patients with PS 0–2 [I, A]
• In any stage of NSCLC, smoking cessation should be highly encouraged, because it improves the outcome [II, A]
Continued
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First-line treatment of EGFR- and ALK-negative NSCLC, PD-L1  50%
• Pembrolizumab is considered a standard first-line option for patients with advanced NSCLC and PD-L1 expression  50% who do not have contraindica-
tions to use of immunotherapy [I, A; ESMO-MCBS v1.1 score: 5]
First-line treatment of NSCLC without actionable oncogenic driver regardless of PD-L1 status
• ChT with platinum doublets should be considered in all stage IV NSCLC patients without an actionable oncogenic driver, without major comorbidities and
PS 0–2 [I, A]
• Platinum-based doublets are the recommended ChT option in all stage IV NSCLC patients with no contraindications to platinum compounds [I, A]
• Four cycles of platinum-based doublets followed by less toxic maintenance monotherapy [I, A], or four cycles in patients not suitable for maintenance
monotherapy [I, A], up to a maximum of six [IV, B], are currently recommended
• The carboplatin/nab-P regimen could be considered a chemotherapeutic option in advanced NSCLC patients, particularly in patients with greater risk of
neurotoxicity, preexisting hypersensitivity to paclitaxel or contraindications for standard paclitaxel premedication [I, B]
• Combinations of platinum-based ChT and anti-PD-(L1) inhibitors have reproducibly demonstrated superiority to standard platinum-based ChT. In the ab-
sence of contraindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy will be
preferred to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%.
• Nivolumab plus ipilimumab represents an optional treatment regimen for patients with NSCLC with a high TMB [I, A; not EMA-approved]
First-line treatment of SCC
• Platinum-based doublets with a third-generation cytotoxic agent (gemcitabine, vinorelbine, taxanes) are recommended in advanced SCC patients without
major comorbidities and PS 0–2 [I, A]
• The addition of necitumumab to cisplatin/gemcitabine has not been adopted as a standard in Europe for advanced SCC and its use should be carefully
evaluated [I, C; ESMO-MCBS v1.1 score: 1]
• Combination of pembrolizumab and carboplatin with paclitaxel or nab-P is a standard choice in patients with metastatic squamous NSCLC [I, A; not EMA
approved]
• The use of atezolizumab with carboplatin and nab-P today represents an option in patients with metastatic squamous NSCLC [I, B; not EMA-approved]
• Other combinations of platinum-based ChT and anti-PD-(L1) inhibitors will demonstrate superiority to standard platinum-based ChT. In the absence of con-
traindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy should be preferred
to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%.
• Nivolumab plus ipilimumab represents an optional treatment regimen for patients with SCC with a high TMB [I, A; not EMA-approved]
First-line treatment of NSCC
• Pemetrexed-based combination ChT is preferred to gemcitabine- or docetaxel-based combinations in patients with non-squamous tumours [II, A]
• Pemetrexed use is restricted to NSCC in any line of treatment in advanced disease [II, A]
• The combination of carboplatin with pemetrexed can be an option in patients with a contraindication to cisplatin [II, B]
• Pembrolizumab in combination with pemetrexed and a platinum-based ChT should be considered a standard option in metastatic non-squamous NSCLC
[I, A; ESMO-MCBS v1.1 score: 4]
• Atezolizumab in combination with pemetrexed and a platinum-based ChT is a therapeutic option in metastatic non-squamous NSCLC [I, B; not EMA-
approved]
• Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel is a therapeutic option in patients with PS 0-1 with metastatic non-
squamous NSCLC, in the absence of contraindications to use of immunotherapy [I, A; not EMA-approved]
• Other combinations of platinum-based ChT and anti-PD-(L1) inhibitors will demonstrate superiority to standard platinum-based ChT. In the absence of con-
traindications and conditioned by the registration and accessibility of anti-PD-(L)1 combinations with platinum-based ChT, this strategy should be preferred
to platinum-based ChT in patients with PS 0-1 and PD-L1 < 50%.
• Nivolumab plus ipilimumab represents an optional treatment regimen for patients with NSCC with a high TMB [I, A; not EMA-approved]
• If PD-(L)1 is not available for ChT combinations, bevacizumab combined with paclitaxel/carboplatin may be offered in the absence of contraindications in
patients with advanced NSCC and PS 0-1 (bevacizumab should be given until progression) [I, A]
• Bevacizumab might be considered with platinum-based regimens beyond paclitaxel/carboplatin in absence of contraindications [II, B]
Maintenance
• Maintenance ChT should be offered only to patients with PS 0–1 after first-line ChT. Decisions about maintenance should consider histology, response to
platinum-doublet ChT and remaining toxicity after first-line ChT, PS and patient’s preference
• In patients with NSCC and PS 0–1, pemetrexed switch maintenance should be considered in patients having disease control following four cycles of non-
pemetrexed containing platinum-based ChT [I, B]
• Pemetrexed continuation maintenance should be considered in patients having disease control following four cycles of cisplatin/pemetrexed [I, A]
• Continuation maintenance with gemcitabine is an option in NSCLC patients treated with four cycles of cisplatin/gemcitabine [I, C]
• Maintenance treatment with erlotinib is only recommended for NSCC patients with an EGFR-sensitising mutation [III, B]
PS 2 and beyond
• ChT prolongs survival and improves QoL in NSCLC patients with PS 2 when compared with BSC [I, A]
• Platinum-based (preferably carboplatin) combination ChT should be considered in eligible PS 2 patients [I, A]. Single-agent ChT with gemcitabine, vinorel-
bine, docetaxel [I, B] or pemetrexed (restricted to NSCC) [II, B] is an alternative treatment option
• The use of checkpoint inhibitors for patients with advanced NSCLC and PS 2 can be considered [III, B]
• Poor PS (3–4) patients should be treated with BSC only in the absence of molecularly targetable alterations, such as EGFR mutations, ALK or ROS1 rearrange-
ments or BRAF V600 mutation [III, B]
Continued
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Elderly patients
• Immunotherapy should be considered according to standard recommendations in elderly patients [III, A]
• Carboplatin-based doublet ChT is recommended in eligible elderly patients with PS 0–2 and with adequate organ function [I, A]
• For those patients not eligible for doublet ChT, single-agent ChT remains the standard of care [I, B]
Second-line treatment of NSCLC without actionable oncogenic driver
• Patients clinically or radiologically progressing after first-line therapy with PS 0–2 should be offered second-line therapy irrespective of administration of
maintenance treatment [I, A]
• In patients with progression after first-line immunotherapy with pembrolizumab, platinum-based ChT is recommended as second-line treatment option [V, B]
• There is a general trend across each of the phase III studies in second-line (nivolumab, pembrolizumab and atezolizumab versus docetaxel) for enriched
efficacy of anti-PD-1/PD-L1 agents in patients with higher PD-L1 expression compared with those with no/less PD-L1 expression. However, unselected
patients may still have improved survival and tolerability with anti-PD-1/PD-L1 agents compared with docetaxel [I, A].
• PD-L1 and PD-1 inhibitors (nivolumab, pembrolizumab and atezolizumab) are the treatment of choice for most patients with advanced, previously treated,
PD-L1-naive NSCLC, irrespective of PD-L1 expression [I, A]
• Nivolumab is recommended in both squamous [I, A; ESMO-MBCS v1.1 score: 5] and non-squamous NSCLC [I, A; ESMO-MBCS v1.1 score: 5]
• Pembrolizumab is recommended in patients with previously treated NSCLC with PD-L1 expression > 1% [I, A; ESMO-MCBS v1.1 score: 5]
• Atezolizumab is recommended in patients with advanced NSCLC previously treated with one or two prior lines of ChT [I, A; ESMO-MCBS v1.1 score: 5]
• In patients not suitable for immunotherapy, second-line ChT is recommended. Comparable options as second-line therapy consist of pemetrexed, for
NSCC only, or docetaxel, with a more favourable tolerability profile for pemetrexed [I, B]
• Treatment may be prolonged if disease is controlled and toxicity acceptable [II, B]
• Nintedanib/docetaxel is a treatment option in patients with adenocarcinoma progressing after previous ChT or immunotherapy [II, B]
• Ramucirumab/docetaxel is a treatment option in patients with NSCLC progressing after first-line ChT or immunotherapy with PS 0–2 [I, B]
• Combination of paclitaxel and bevacizumab is another treatment option [I, C] but it is not EMA-approved
• Erlotinib represents a potential second/third-line treatment option in particular for patients not suitable for immunotherapy or second-line ChT in
unknown EGFR status or EGFR WT tumours [II, C]
• In patients with advanced SCC with PS 0–2 unfit for ChT or immunotherapy, afatinib is a potential option with unknown EGFR status or EGFR WT patients
[I, C; ESMO-MCBS v1.1 score: 2]
First-line treatment of EGFR-mutated NSCLC
• Patients with a tumour with a sensitising EGFR mutation should receive first-line EGFR TKIs including erlotinib, gefitinib or afatinib [I, A]. None of the three
EGFR TKIs is consensually considered as a preferred option [IV, C]
• Dacomitinib will be added to the list when the drug will be approved by regulatory agencies, the United States FDA and the EMA [I, A]
• First-line osimertinib is now considered one of the options for patients with a tumour with sensitising EGFR mutations [I, A; MBCS score v1.1 score: 4]
• All patients should be considered for EGFR TKIs irrespective of clinical parameters, including PS, gender, tobacco exposure, histology and line of therapy [I, A]
• Erlotinib/bevacizumab represents a front-line treatment option in patients with EGFR-mutated tumours [II, B; ESMO-MCBS v1.1 score: 3]
• Addition of carboplatin and pemetrexed to gefitinib represents a first-line option in patients with EGFR-mutated tumours [I, B; not EMA-approved]
• Patients who have radiological progression with ongoing clinical benefit may continue with EGFR TKI [II, A]
• In EGFR-mutated NSCLC patients with localised distant progression and ongoing systemic control, continuation of treatment with EGFR TKI in combination
with local treatment of progressing metastatic sites may be considered [III, B]
Second-line treatment of EGFR-mutated NSCLC
• EGFR TKI should be stopped at the time when patient starts ChT for treatment of TKI resistance [I, A]
• All tumours with clinical evidence of EGFR TKI resistance, not previously treated with osimertinib, should be tested for presence of EGFR exon 20 T790M
mutation [I, A]
• Liquid biopsy can be used as the initial test for detection of T790M mutation, and if tested negative, re-biopsy should be attempted if feasible [II, A]
• Osimertinib is the standard therapy for patients whose tumours are tested positive for T790M either in liquid biopsy or re-biopsy, if not received previously
[I, A; ESMO-MCBS v1.1 score: 4]
• In EGFR-mutated NSCLC with CNS disease, osimertinib is highly active
• Platinum-based doublet is the standard therapy for patients whose tumour is tested T790M negative in either re-biopsy or in liquid biopsy (only when
re-biopsy is not feasible) [I, A]
• Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel should be considered as a therapeutic option in patients with EGFR-
mutated tumour, PS 0–1, in absence of contraindications to use of immunotherapy after targeted therapies have been exploited [III, A; not EMA-approved]
First-line treatment of ALK-rearranged NSCLC
• Patients with ALK-rearranged NSCLC should receive first-line ALK TKI including crizotinib [I, A; ESMO-MBCS v1.1 score: 4], ceritinib [I, B; ESMO-MCBS v1.1
score: 4], alectinib [I, A] or brigatinib [I, B; not EMA-approved]
• Alectinib is associated with longer PFS and lower toxicity than crizotinib and showed activity against CNS disease in patients previously untreated with ALK-
positive NSCLC [I, A]
• Brigatinib is associated with longer PFS than crizotinib at the first interim analysis and showed activity against CNS disease in previously untreated patients
with ALK-positive NSCLC [I, B, not EMA approved]
• In patients with CNS involvement, front-line use of ALK TKIs is effective, and alectinib [III, A], brigatinib [III, B] or ceritinib [IV, B] are recommended. Ceritinib
represents a better treatment strategy than ChT [I, B] and presumably crizotinib [IV, B]; alectinib represents a better treatment option than crizotinib [I, A];
brigatinib represents a better treatment option than crizotinib [I, B; not EMA-approved]
• In ALK-rearranged NSCLC patients with localised distant progression and ongoing systemic control, continuation of treatment with ALK TKI in combination
with local treatment of progressing metastatic sites may be considered [III, B]
Continued
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Second and further lines of treatment of ALK-rearranged NSCLC
• Any patient with NSCLC harbouring an ALK fusion should receive crizotinib as next-line therapy, if not received previously [I, A]
• Ceritinib and alectinib are recommended in patients with ALK-positive advanced NSCLC who progress on treatment with or are intolerant to crizotinib
[I, A; ESMO-MBCS v1.1 score: 4]
• In patients with ALK-positive NSCLC progressing on crizotinib with CNS progression, treatment should be a next-generation ALK TKIs such as alectinib or
ceritinib [I, A]. In patients who progress after a second-generation ALK TKI, the next-generation ALK inhibitors such as brigatinib or lorlatinib are an option if
available [III, B]. They are currently not approved by the EMA
Treatment of ROS1-rearranged NSCLC
• Crizotinib is recommended in the first-line setting in patients with stage IV NSCLC with ROS1 rearrangement [III, A; ESMO-MBCS v1.1 score: 3]
• In patients with ROS1-positive NSCLC, who have not received crizotinib in the first-line setting, single-agent crizotinib may be offered as second-line
therapy [III, A]
• Ceritinib might be considered in crizotinib-naive patients but is currently not approved by the EMA [III, C]
• If patients have received crizotinib in the first-line setting, then they may be offered platinum-based ChT therapy in the second-line setting [IV, A]
Treatment of BRAF-mutated NSCLC
• Patients with stage IV NSCLC with BRAF V600 mutation should be exposed in first or second line to BRAF/MEK inhibition using dabrafenib/trametinib
[III, A; ESMO-MBCS v1.1 score: 2]
• If patients have received BRAF/MEK inhibition in the first-line setting, then they may be offered platinum-based ChT in the second-line setting [IV, A]
Patients with NSCLC with other actionable oncogenic driver
• Targeting RET is not currently routinely recommended and recruitment into open trials is encouraged [III, C]
• Targeting MET amplification is not currently routinely recommended and recruitment into open trials is encouraged [III, C]
• Targeting METex14 variants (while evidence of benefit is stronger) is not currently routinely recommended and recruitment into open trials is encouraged
[III, C]
• Crizotinib has demonstrated potential clinical efficacy for METex14 variant NSCLC that needs to be confirmed [III, C]
• Given the paucity of robust data, targeting HER2 dysregulation is not currently recommended and recruitment into open trials is encouraged [III, C]
• Targeting NRTK fusions is not currently recommended and recruitment into open trials is encouraged [III, C]
Role of RT in stage IV
• EBRT is indicated in cases of haemoptysis and symptomatic airway obstruction [III, B]
• RT can achieve symptom control for a variety of clinical scenarios including haemoptysis, symptomatic airway obstruction, painful chest wall disease and
bone metastasis, superior vena cava syndrome, soft tissue or neural invasion [II, B]
• Administration of high-dose RT does not result in greater levels of palliation [II, B]
• EBRT alone is more effective for palliation than EBB alone [II, B]
• For patients previously treated by EBRT who are symptomatic from recurrent endobronchial central obstruction, EBB may be considered in selected cases
[III, C]
• Neurological symptoms from spinal cord compression can be relieved by early RT [II, B]
Brain metastases
• WBRT can be considered in selected patients, contingent on prognostic factors of better survival [III, C]. WBRT should not be offered in RPA class III patients
in view of the dismal prognosis [I, A]; only BSC is recommended
• The most frequent WBRT schedules are 20 Gy in 5 fractions or 30 Gy in 10 fractions, with no difference in outcome [I, A]
• For most patients with symptomatic brain metastases and/or significant oedema, dexamethasone or equivalent corticosteroid is recommended [III, A]
• Neuroprotective agents are not recommended for routine use [II, C]
• Hippocampus avoidance WBRT is not currently recommended as a standard treatment [III, C]
• In case of single brain metastases surgical resection can be considered [III, B]
• Postoperative WBRT or SRS is recommended after surgical resection [I, A]
• In the case of a limited number of metastasis, SRS alone is the recommended treatment in patients with RPA class I–II [III, B]
• SRS alone, without WBRT but with close MRI brain imaging follow-up, is an alternative strategy [III, B]
• The indication for SRS is based on total tumour volume rather than numbers of metastases, as the risk of radionecrosis increases with tumour volume [III, C]
• In patients with asymptomatically detected CNS metastases at presentation, systemic therapy with deferred RT should be considered due to similar
intracranial and extra cranial response [II, B]
• In patients with an actionable oncogenic driver (e.g. EGFR, ALK) and clinically asymptomatic brain metastases, next-generation TKIs may restore control of
brain disease and delay cranial RT [II, A]
• There is currently limited trial data demonstrating safety and efficacy of immunotherapy in patients with small-volume untreated CNS metastases [III, B]
LM carcinomatosis
• A high index of suspicion should be borne for LM involvement especially in patients with actionable oncogenic drivers having TKI treatment [V]. CSF
sampling is diagnostic of LMD but limited by low sensitivity, albeit with high specificity [IV, A]
• Patients with actionable oncogenic drivers and LMD can be treated with CNS-penetrant next-generation TKIs [III, B]
• ChT and bevacizumab may have activity both extra-cranially and intra-cranially, and also in the context of LMD [IV, C]
• Intra-CSF pharmacotherapy can be considered contingent on clinical factors [V, C]
• In exceptional cases, focal RT can be considered for circumscribed, notably symptomatic, lesions [V, C]
Continued
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Somatic fusions involving the neurotropic tropomyosin recep-
tor kinase genes (NTRK1-3) are rare oncogenic drivers occurring
at low prevalence (< 1%) in a variety of tumours including
NSCLC [252], again typically in adenocarcinomas (although
non-adenocarcinoma cases are reported) and never-smokers.
The rarity of these fusions across different cancer types has
resulted in basket trial design for drug development. NRTK1-3
fusions encode oncogenic TRKA-C fusion proteins, respectively,
that can be targeted by therapies in development, including laro-
trectinib (LOXO-101) and entrectinib (RXDX-101) [253–256].
Both have demonstrated marked durable responses in NTRK
fusion-positive NSCLC in early reports from ongoing single
Surgery in stage IV
• Surgery may be indicated for diagnosis, evaluation of response to systemic therapy and palliation
• Highly selected patients may be considered for lung resection with therapeutic intent or even for a salvage procedure [IV, C]
• When metastatic disease is suspected on PET scanning, invasive surgical procedures such as incisional biopsies, mediastinoscopy, thoracoscopy (VATS) or
laparoscopy may be required to obtain relevant biopsy samples. Adequate samples should be provided to the pathologist for detailed routine staining,
IHC and molecular genetic testing [III, B]
• Persisting or recurrent pleural effusions are usually managed by pleurodesis to improve dyspnoea. Talc is the preferred agent and thoracoscopic poudrage
may be better than injection of talc slurry in patients with primary lung cancer [II, B]
• In case of a trapped lung by a thickened visceral pleural peel, indwelling pleural catheters or pleuroperitoneal shunts provide symptomatic relief [IV, B]
Treatment of oligometastatic disease
• Stage IV patients with one to three synchronous metastases at diagnosis may experience long-term DFS following systemic therapy and local consolidative
therapy (high-dose RT or surgery) [III, B]. Because of the limited evidence, these patients should be discussed within a multidisciplinary tumour board [II, B],
and inclusion in clinical trials is preferred
• Although operative risk is low and long-term survival may be achieved, current evidence for surgery in oligometastatic disease is limited, and the relative
contribution of surgery versus RT as local treatment modality has not been established yet
• Stage IV patients with limited metachronous metastases may be treated with a radical local therapy (high-dose RT or surgery) and may experience long-
term DFS [IV, B]. However, this is based mainly on retrospective data and inclusion in clinical trials is preferred
• Stage IV patients with driver mutations, with oligoprogression while on molecular-targeted therapy, may be treated with a radical local treatment (high-
dose RT or surgery) and may experience long-term DFS [IV, C]. However, this is based mainly on retrospective data and inclusion in clinical trials is preferred
• Solitary lesions in the contralateral lung should, in most cases, be considered as synchronous secondary primary tumours and, if possible, treated with
curative-intent therapy [IV, B]
Bone metastases
• Zoledronic acid reduces SREs (pathological fracture, radiation/surgery to bone or spinal cord compression) [II, B] and is recommended in stage IV bone
metastatic disease [I, B]
• Denosumab shows a trend towards superiority to zoledronic acid in lung cancer in terms of SRE prevention [II, B] and is recommended in selected patients
with advanced lung cancer with bone metastases [I, B]
• In the case of uncomplicated painful bone metastases, single fraction EBRT is the recommended treatment on the basis of non-inferiority to multiple frac-
tion RT [I, A]
Role of minimally invasive procedures in stage IV NSCLC
• In case of symptomatic major airways obstruction or post-obstructive infection, endoscopy debulking by laser, cryotherapy or stent placement may be
helpful [III, C]
• Endoscopy is useful in the diagnosis and treatment (endobronchial or by guiding endovascular embolisation) of haemoptysis [III, C]
• Vascular stenting might be useful in NSCLC-related superior vena cava compression [III, B]
Palliative care in stage IV NSCLC
• Early palliative care intervention is recommended, in parallel with standard oncological care [I, A]
Follow-up
• Close follow-up, at least every 6–12 weeks after first-line therapy, is advised to allow for early initiation of second-line therapy but should depend on
individual retreatment options [III, B]
ALK, anaplastic lymphoma kinase; BSC, best supportive care; CEA, carcinoembryonic antigen; cfDNA, cell-free DNA; ChT, chemotherapy; CNS, central ner-
vous system; CSF, cerebrospinal fluid; CT, computed tomography; DFS, disease-free survival; EBB, endobronchial brachytherapy; EBRT, external beam radio-
therapy; EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; ESMO-MCBS, European Society for
Medical Oncology-Magnitude of Clinical Benefit Scale; EUS, endoscopic ultrasound; FDA, Food and Drug Administration; FISH, fluorescent in situ hybridisa-
tion; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; imRECIST, immune-modified RECIST; iRECIST, immune RECIST; irRECIST,
immune-related RECIST; LM, leptomeningeal; LMD, leptomeningeal disease; MEK, mitogen-activated protein kinase; MRI, magnetic resonance imaging;
nab-P, albumin-bound paclitaxel; NGS, next-generation sequencing; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; NSCLC-NOS,
non-small cell lung cancer-not otherwise specified; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PET, positron emission
tomography; PFS, progression-free survival; PS, performance status; QoL, quality of life; RECIST, Response Evaluation Criteria in Solid Tumours; RPA, recursive
partitioning analysis; RT, radiotherapy; SCC, squamous cell carcinoma; SRE, skeletal-related event; SRS, stereotactic radiosurgery; TKI, tyrosine kinase inhibitor;
TMB, tumour mutational burden; UICC, Union for International Cancer Control; VATS, video-assisted thorascopic surgery; WBRT, whole-brain radiotherapy;
WHO, World Health Organization; WT, wild-type.
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arm basket studies but are not currently recommended for rou-
tine care and recruitment into open trials is therefore encouraged
[III, C].
Role of radiotherapy in stage IV NSCLC
External beam radiotherapy (EBRT) plays a major role in the
symptom control of metastases, such as painful chest wall disease,
painful bone metastasis, superior vena cava syndrome, soft tissue
or neural invasion. EBRT is indicated in cases of haemoptysis and
symptomatic airway obstruction [III, B]. A Cochrane systematic
review of palliative EBRT regimens for patients with thoracic
symptoms from NSCLC included 14 RCTs (3576 patients) [257].
Doses of radiation ranged from 10 Gy in 1 fraction to 60 Gy in 30
fractions, with a total of 19 different dose/fractionation regimens.
There was no strong evidence that any regimen achieved a greater
level of palliation [II, B]. Furthermore, higher dose regimens were
associated with higher rates of acute toxicity. However, it should
be noted that the studies were heterogeneous and most were con-
ducted in the 1980s and 1990s, therefore using dated radiotherapy
(RT) techniques. There are few data on the optimal timing of thor-
acic RT and systemic therapy in the stage IV NSCLC setting.
Furthermore, there is no evidence to date that the concurrent ad-
ministration of ChT, targeted agents or immunotherapy to pallia-
tive RT is beneficial in this group of patients.
Another method of palliation of thoracic symptoms is endo-
bronchial brachytherapy (EBB). The effectiveness of EBB com-
pared with EBRT or other alternative endoluminal treatments
was assessed in a Cochrane systematic review [258]. The authors
concluded that EBRT alone is more effective for palliation than
EBB alone [II, B]. However, evidence was limited with regard to
the comparison of EBB plus EBRT over EBRT alone for symptom
relief. For patients previously treated by EBRT who are symptom-
atic from recurrent endobronchial central obstruction, EBB may
be considered in selected cases [III, C].
Neurological symptoms from spinal cord compression can be
relieved by early RT [II, B] [259].
Focus on brain metastases
CNS metastases are commonly identified with NSCLC, predomin-
antly with adenocarcinoma. LMD is a deadly complication of solid
tumours and is associated with a poor prognosis. Adenocarcinomas
are the most common tumours to metastasise to the CNS. Of the
patients with NSCLC, 30%–64% have CNS metastases, of which
4%–7% present LMD [260]. Incidence and prevalence of LMD are
both increasing due to brain metastases screening, better imaging
modalities as well as prolongation of patients’ survival.
Presence of malignant cells on CSF cytology provides the gold-
standard for diagnosing leptomeningeal (LM) carcinomatosis.
Abnormalities on imaging can be found in 70%–80% of patients
with LMD and the imaging modality of choice is high quality, T1-
weighted MRI with gadolinium contrast, which has been shown to
be more sensitive compared with contrast-enhanced CT [261, 262].
The treatment of patients with brain metastases, with/without
LM involvement and no driver mutations, is dependent on the
prognosis. Prognosis can be estimated based on the Radiation
Therapy Oncology Group recursive partitioning analysis (RPA):
class I patients are those< 65 years old, with a good PS [Karnofsky
Index (KI)  70%], no other extracranial metastases and a con-
trolled primary tumour; class III patients have a KI < 70%; and
class II represents all other patients [263]. In RPA class III patients,
RT is not recommended in view of the dismal prognosis [I, A];
only BSC is recommended, as their median survival is generally <
2 months. The role of whole-brain RT (WBRT) in unselected
patients has been questioned by the QUARTZ trial data, a phase III
non-inferiority study, in which patients were randomised to either
BSC including dexamethasone plus WBRT 20 Gy in 5 daily frac-
tions or to the same BSC without WBRT [264]. This trial demon-
strated no difference between the treatment arms regarding the
relief of symptoms, steroid use, OS, QoL or quality-adjusted life
years in the intention-to-treat (ITT) population, confirming no
benefit for WBRT in the RPA class III subset [I, A]. However, the
median survival in the trial was poor (8.5–9.2 weeks) and the trial
recruited over 7 years, a time during which considerable advances
Table 6. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service
Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses
of well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials
or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, expert opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
aBy permission of the Infectious Diseases Society of America [324].
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in molecular selection, systemic therapy, stereotactic radiosurgery
(SRS) patient selection and MRI brain surveillance have been
implemented. A signal for WBRT benefit was seen for younger
patients with better Karnofsky PS and either controlled primary or
no extracranial disease. WBRT can therefore be considered for
patients contingent on prognostic factors of better survival such as
driver mutations [III, C].
The most frequent WBRT schedules are 20 Gy in 5 fractions or
30 Gy in 10 fractions, with no difference in outcome [I, A] [265].
For most patients with symptomatic brain metastases and/or sig-
nificant oedema, dexamethasone or equivalent corticosteroid is
recommended [III, A] [266]. Tapering of the dose and, if pos-
sible, cessation after RT, are recommended. Corticosteroids are
not recommended in the case of asymptomatic brain metastases.
WBRT may be associated with delayed progressive cognitive im-
pairment in responders, as tumour progression affects this par-
ameter more than radiation toxicity [267]. Neuroprotective
agents have not shown a convincing role and are not recom-
mended for routine use [II, C], with a small phase III trial of
memantine on 149 assessable patients (RTOG 0614) suggesting
benefit [268]. Hippocampus avoidance WBRT has been shown to
be probably safe [269], but is still undergoing trial evaluation and
is not currently recommended for routine care [III, C].
Recent data showed that SRS can be considered as another stand-
ard of care for this patient population as a less toxic alternative to
WBRT. SRS of the surgical cavity in patients who have had complete
resection of 1–3 brain metastases significantly lowers local recur-
rence compared with that noted for observation alone [270].
In case of single brain metastases surgical resection can be con-
sidered [III, B] [271–273]. Postoperative WBRT or SRS is gener-
ally recommended after surgical resection [I, A] [274].
Another treatment strategy, in the case of a limited number of
metastases and RPA class I and II, is SRS alone [III, B] [275–278].
The randomised trials evaluating SRS have included patients with
1–4 brain metastases. SRS has increasingly become the favoured
modality due to reduced morbidity compared with WBRT, but it
should be noted that there is no randomised trial comparing SRS
alone to WBRT. A survival advantage in favour of WBRT plus
SRS has been demonstrated against WBRT but only for the sub-
group of patients with a single brain metastasis [279]. The major-
ity of studies evaluating WBRT in addition of SRS or
neurosurgery have shown a decline in cognitive function in the
combined arm [278, 279]. SRS alone with close follow-up, with-
out WBRT consolidation, is therefore a recommended strategy
[III, B].
Although it is generally accepted that SRS should generally be
considered in patients with  4 brain metastases, a prospective
observational study from Japan challenged this prevailing con-
cept [280]. The study enrolled 1194 eligible patients (76% had
lung cancer) with 1 to 10 newly diagnosed brain metastases, lon-
gest diameter < 3 cm, largest tumour < 10 mL in volume and a
total cumulative volume of  15 mL. OS did not differ between
patients treated with SRS with 2-4 metastases and those with 5-10
metastases. This study therefore suggested the use of tumour vol-
ume and absolute size, rather than the number of metastases, as
treatment criteria. In some territories, the indication for SRS is
now based on total tumour volume rather than number of meta-
stases, as the risk of radionecrosis increases with tumour volume
[III, C] [278]. In patients undergoing SRS, radionecrosis is a chal-
lenging complication to manage.
In patients with asymptomatic brain metastases who have not
yet received prior systemic therapy (i.e. ChT, TKIs), treatment
with upfront systemic therapy and deferred RT should be consid-
ered, with trial data suggesting similar intracranial and extra-
cranial ORRs [II, B] [281, 282]. In patients suitable for first-line
immune-checkpoint inhibitor therapy, CNS metastases were
generally mandated to have been treated before therapy, with evi-
dence of intracranial response. There is currently limited trial
data demonstrating safety and efficacy of immunotherapy in
patients with small-volume untreated CNS metastases [III, B]
[283].
Among those patients with an actionable oncogenic driver
(e.g. EGFR, ALK), between 44% and 60% develop brain metasta-
ses in the course of their disease [284, 285]. In such patients, the
use of CNS-penetrant next-generation TKIs (e.g. osimertinib,
alectinib, ceritinib) may restore control of brain disease, thereby
potentially delaying cranial RT [II, A] [53, 187, 200]. Moreover,
next-generation TKIs may also reduce the incidence of new CNS
metastases, thereby significantly postponing the time to need
CNS RT [53].
Focus on LM carcinomatosis
LMD may present with non-specific neurological symptoms
(headaches, nausea, vomiting) as well as discrete signs due to the
CNS area involved (gait difficulties, cranial nerve palsies), and a
high index of suspicion is required, particularly in those with ac-
tionable oncogenic drivers due to higher prevalence [V].
Diagnostic modalities include cerebrospinal MRI with contrast
enhancement, ideally before CSF intervention. CSF sampling
with cytological assessment is diagnostic but limited by low sensi-
tivity but high specificity [IV, A]. The prognosis from LMD due
to NSCLC is poor, and treatment aim is to prolong survival with
acceptable QoL. Patients with actionable oncogenic drivers may
derive benefit from a CNS-penetrant next-generation TKI as per
those with brain metastases [III, B]; otherwise, systemic therapy
strategies vary widely across Europe. ChT and bevacizumab may
have activity both extra-cranially and intra-cranially, and also in
the context of LMD [IV, C] [126, 286]. Intra-CSF pharmacother-
apy may be considered through either repeated lumbar punctu-
res, a reservoir or ventricular device, although consideration
should be given to patient factors, e.g. PS, extra-cranial control
and likely benefit [V, C]. No randomised data exist to support the
role of RT for LMD. In exceptional cases, focal RT can be consid-
ered for circumscribed, notably symptomatic, lesions [V, C].
Role of surgery in stage IV NSCLC
As prognosis in the majority of patients with stage IV NSCLC is
poor, the role of surgery is traditionally limited in this patient
group. However, with the widespread introduction of targeted
therapies and immunotherapy improving prognosis in specific
subcategories, the role of thoracic surgery is currently redefined.
At the present time, surgery may be indicated for diagnosis,
evaluation of response to systemic therapy and palliation, and
highly selected patients may be considered for lung resection with
therapeutic intent or even for a salvage procedure. In the last two
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categories, surgery can be carried out with a mortality < 2%, a
low morbidity rate and 5-year survival rates in the range of 11%–
30% in retrospective series [IV, C] [287, 288]. Whether there is a
significant difference between synchronous and metachronous
metastases and between different distant sites has not been clearly
established and more prospective data are needed.
When metastatic disease is suspected on PET scanning, invasive
surgical procedures such as incisional biopsies, mediastinoscopy,
thoracoscopy (VATS) or laparoscopy may be required to obtain
relevant biopsy samples. Examples include patients with contralat-
eral lung nodules, distant metastases or suspicion of mediastinal
nodal involvement who do not qualify for minimally invasive
biopsies or in whom results of the latter are equivocal. Adequate
samples should be provided to the pathologist for detailed routine
staining, IHC and molecular genetic testing [III, B].
Palliative interventions may be useful in case of local complica-
tions related to the primary tumour or metastatic foci which can-
not be managed by conservative measures, e.g. lung abscess,
empyema, massive haemoptysis, spinal cord compression and
pathological bone fractures.
In the 8th edition of the tumour, node, metastasis (TNM) clas-
sification a new subcategory was introduced comprising patients
with one metastasis in a single distant organ, defined as M1b dis-
ease, in contrast to patients with multiple metastases in one or
more distant organs, currently M1c disease [289]. There is no
general consensus on the precise definition of oligometastatic dis-
ease and clear evidence for surgical treatment is limited, as only
relatively small prospective series are available [III, B] [290–292].
Prospective series suggest that complete surgical resection is ne-
cessary to obtain long-term survival and that mediastinal nodal
involvement carries a poor prognosis [293]. This is further dis-
cussed in the section ‘Treatment of oligometastatic NSCLC’.
A specific subgroup consists of patients with malignant pleural
nodules or malignant pleural effusion [293]. Extensive surgical
procedures consisting of extrapleural pneumonectomy some-
times in combination with intraoperative ChT or hyperthermic
ChT, have been described when extrathoracic metastases or me-
diastinal lymph node involvement have been excluded [294,
295]. However, these interventions carry a higher operative risk
and prospective studies are currently not yet available [IV, D].
Persisting or recurrent pleural effusions are usually managed by
pleurodesis to improve dyspnoea. Talc is the preferred agent and
thoracoscopic poudrage may be better than injection of talc
slurry in patients with primary lung cancer [II, B] [296, 297]. In
case of a trapped lung by a thickened visceral pleural peel, indwel-
ling pleural catheters or pleuroperitoneal shunts provide symp-
tomatic relief [IV, B] [298, 299].
Lastly, salvage surgery may be considered in case of residual or
progressive disease in the primary tumour or metastatic site
when no other treatment options remain or specific complica-
tions occur, such as formation of a lung abscess in a necrotic cav-
ity [300]. Long-term survival may be obtained in selected
patients with limited distant involvement, but only case reports
have been published so far [V, C] [301].
In a recent retrospective analysis of the National Cancer
Database, a cohort of 300 572 patients with stage IIIA, IIIB or IV
NSCLC were studied, of whom 4568 had a surgical intervention
for stage IV disease [302]. A surgical selection score could be con-
structed comprising histology, tumour size, TNM status,
Charlson comorbidity index, age, race, facility type, insurance
and income. In a logistic regression model this score was found to
be a good predictor of survival. However, it should be noted that
further prospective validation is necessary, and that the relative
contribution of surgery versus RT in a multimodality setting for
stage IV disease was not studied in this analysis.
Treatment of oligometastatic disease
The growing interest in oligometastases is based on the concept
that long-term disease control, or even cure, may be achieved in
some subgroups of these patients with aggressive local treatment
of distant metastases (surgery or high-dose RT) [303]. The term
‘oligometastases’ refers to a limited number of distant metastases,
although there is no consensus on the appropriate cut-off to de-
fine the oligometastatic state. Almost all published clinical trials
investigating local treatment of oligometastatic disease have lim-
ited inclusion to patients with  5 metastases. In addition, the
vast majority of the trials included patients with  3 metastases
and in an individual patients meta-analysis published in 2014, al-
most 90% of the patients had a single metastasis [303]. Some
studies also limited the number of organs in which these metasta-
ses are present [304]. It should be noted that many of these stud-
ies did not include PET-CT staging.
Oligometastases can be either synchronous, when a patient
presents with a limited number of metastases at initial diagnosis,
or metachronous when metastases are identified after treatment
of the primary tumour [305]. The biology of synchronous and
metachronous oligometastases may differ as illustrated by the
fact that patients with metachronous presentation have a better
prognosis [303]. In patients receiving systemic therapy (mainly
in tumours with driver mutations treated with TKIs), the term
oligoprogression can be also applied in the case of progression of
a limited number of metastatic lesions, when all the other lesions
remain stable. Clinical trials are ongoing in this setting.
In this heterogeneous group of patients with oligometastases,
the specific approach to oligometastases in the brain has been dis-
cussed above. Another subgroup requiring further discussion is
that of patients with a solitary lesion in the contralateral lung.
The International Association for the Study of Lung Cancer
(IASLC) Staging and Prognostic Factors Committee carried out a
systematic literature review, aiming at distinguishing a second
primary from a metastasis in patients who have more than one
pulmonary nodule [306]. This review concluded that few features
are definitive, with many commonly used factors being suggest-
ive, but carry a substantial risk of misclassification as the majority
of second primary lung tumours are of the same histology. For
these cases, the IASLC recommended a careful review by a multi-
disciplinary tumour board, and pursuit of radical therapy, such
as that for a synchronous secondary primary tumour, when pos-
sible. Both surgery [307, 308] and SRS [309, 310] have been
shown to result in long-term survivors in this setting [IV, B].
A systematic literature review identified 757 NSCLC patients
treated with 1–5 (88% single metastases) synchronous or metachro-
nous metastases [303]. These patients had a median age at diagnosis
of 61 years, 98% had a good PS and two-thirds of patients had early-
stage intrathoracic disease staged IA–IIB (after excluding metastatic
disease). Surgery was the most common treatment modality for
both primary (n¼ 635, 83.9%) and metastases (n¼ 339, 62.3%).
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Predictive factors for OS were synchronous versus metachronous
metastases (P< 0.001), N-stage (P¼ 0.002) and adenocarcinoma
histology (P¼ 0.036). RPA for risk groups identified a good progno-
sis (low-risk) group presenting with metachronous metastases (5-
year OS of 48%), an intermediate-risk group presenting with syn-
chronous metastases and N0 disease (5-year OS of 36%) and, finally,
a high-risk group presenting with synchronous metastases and
intrathoracic N1/N2 disease (5-year OS of 14%). Caution is war-
ranted before concluding that positive outcomes in these patients
are due solely to the treatment intervention, rather than patient se-
lection or other biases [305].
Stage IV patients with limited synchronous metastases at diag-
nosis may experience long-term disease-free survival (DFS) fol-
lowing systemic therapy and local consolidative therapy [LCT:
high-dose RT including stereotactic ablative body RT (SABR) or
surgery] [III, B]. Five phase II trials evaluating LCT in patients
with NSCLC and synchronous oligometastases have been pub-
lished. Three of these studies are small, single arm studies which
generally showed durable PFS in a subgroup of patients [290,
291, 311]. Two out of the five studies are randomised phase II
studies that were stopped early after interim analysis. The first
study randomised NSCLC patients between maintenance therapy
(RT or surgery) in patients with 3 metastases, without progres-
sion after first-line systemic therapy (n¼ 49). There was a signifi-
cant difference in PFS time between the two groups (mPFS
11.9 months in the LCT group versus 3.9 months in the mainten-
ance group; HR¼ 0.35, P¼ 0.005) [292]. The second study rand-
omised patients with  5 metastatic sites between maintenance
ChT alone versus SABR followed by maintenance ChT (n¼ 29)
[312]. So far, there are no published data on the impact of LCT
on OS and long-term toxicity. Several clinical trials are ongoing
to evaluate these important endpoints.
Stage IV patients with limited metachronous metastases may
be treated with a local treatment as some may experience long-
term DFS [IV, B]. However, this is based mainly on retrospective
data. Although operative risk is low and long-term survival may
be achieved, current evidence for surgery in oligometastatic dis-
ease is limited, and the relative contribution of surgery versus RT
as local treatment modality has not yet been established. Solitary
lesions in the contralateral lung should, in most cases, be consid-
ered as synchronous secondary primary tumours and, if possible,
treated with curative-intent therapy [IV, B].
Similarly, there are few prospective data to support this treat-
ment approach in patients with driver mutations who present
with oligoprogression on molecular-targeted therapies [IV, C].
Furthermore, there is little data on the safety of combining SABR
with molecularly targeted agents.
Some recommendations for the implementation of standard of
care and advanced imaging modalities for identifying and follow-
ing up patients with oligometastatic disease have been published
by the European Organisation for Research and Treatment of
Cancer (EORTC) imaging group [313]. In the synchronous,
metachronous and oligoprogessive setting, because of the limited
evidence available, inclusion in clinical trials is preferred.
Focus on bone metastases
Given the incidence of bone metastases in NSCLC (30%–40% of
patients with NSCLC develop bone metastases), it may be
reasonable to evaluate for bone disease upon disease diagnosis. In
general, the management aim is to palliate symptoms and prevent
complications. Palliative RT is highly effective, usually with rapid
pain relief. Both standard EBRT and SABR can be used to palliate
painful, uncomplicated bone pain. However, the data on efficacy
and safety of SABR are mainly from retrospective single institu-
tion studies. Systematic reviews of palliative RT trials for bone
metastases showed that single and multiple fraction regimens
provided equal pain relief; however, retreatment rates were sig-
nificantly higher in patients receiving single fraction treatment [I,
A] [314, 315].
Zoledronic acid reduces skeletal-related events (SREs) (patho-
logical fracture, radiation/surgery to bone or spinal cord com-
pression) [II, B] [316]. Denosumab shows a trend towards
superiority to zoledronic acid in lung cancer in terms of SRE pre-
vention [II, B] [317]. In an exploratory analysis of a large phase
III trial, denosumab was associated with improved mOS in the
subgroup of 702 metastatic NSCLC patients [318]. In the study of
denosumab versus zoledronic acid in patients with advanced can-
cers, the time extent to which pain interfered with daily life (used
as surrogate for QoL) was longer in patients treated with denosu-
mab and with no pain or mild pain interference at baseline [319].
Both agents are associated with increased risk of osteonecrosis of
the jaw. Zoledronic acid or denosumab are thus recommended in
selected patients with advanced lung cancer with bone metastases
[I, B]. Patients should be selected if they have a life expectancy of
> 3 months and are considered at high risk of SREs.
Role of minimally invasive procedures in stage IV
NSCLC
Endoscopy has a role to play in palliative care, notably in case of
symptomatic major airway obstruction or post-obstructive infec-
tion, where endoscopic debulking by laser, cryotherapy or stent
placement may be helpful [III, C]. Endoscopy is useful in the diag-
nosis and treatment (endobronchial or by guiding endovascular
embolisation) of haemoptysis [III, C]. Vascular stenting might be
useful in NSCLC-related superior vena cava compression [III, B].
Role of palliative care in stage IV NSCLC
Early palliative care intervention is recommended, in parallel
with standard oncological care [I, A], with evidence demonstrat-
ing that palliative care interventions significantly improve QoL.
Two randomised trials evaluating the impact of introducing spe-
cialised palliative care early after diagnosis of stage IV disease on
patient QoL in ambulatory patients were able to show improve-
ments in QoL and mood, and, in one trial, a reduction in aggres-
sive treatment and an improvement in mOS [320, 321].
Follow-up, long-term implications and
survivorship
The optimal approach to post-treatment management of patients
with NSCLC, including the role of radiological evaluation, is con-
troversial, with very limited literature available. Due to the ag-
gressive nature of this disease, generally close follow-up, at least
every 6–12 weeks after first-line therapy, is advised to allow for
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early initiation of second-line therapy but should also depend on
individual retreatment options [III, B].
Methodology
These Clinical Practice Guidelines were developed in accordance
with the ESMO standard operating procedures for Clinical Practice
Guidelines development, http://www.esmo.org/Guidelines/ESMO-
Guidelines-Methodology. The relevant literature has been selected
by the expert authors. A summary of recommendations is provided
in Table 4. A MCBS table with ESMO-MCBS scores is included in
Table 5. ESMO-MCBS v1.1 was used to calculate scores for new
therapies/indications approved by the EMA since 1 January 2016
[322]. Levels of evidence and grades of recommendation have been
applied using the system shown in Table 6; some statements may be
accompanied by a grade of recommendation alone. Statements
without grading were considered justified standard clinical practice
by the experts and the ESMO faculty.
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